var title_f16_48_17152="Cytokines in scleroderma";
var content_f16_48_17152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Paracrine interactions between cells involved in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 277px; background-image: url(data:image/gif;base64,R0lGODlhHgIVAfcAAP///wBmZoCAgP/MzAAAAMDAwEBAQMzMzKCgoMxmZvDw8CAgIMyZmVBQUNDQ0LCwsDAwMODg4GBgYBAQEHBwcH9/f5CQkE1NTWZmZn9mZgAzMwAAZn+ZmdnZ2Sp3dxkZGQAZGT8/PwBMTL+/v1WIiGYzMwBfXwAGBqDGxgA/PwwMDIyMjD8zM/D29oCzswATE7+ZmaqqqgAMDGxsbFCWlgAfH38/PwpqasDZ2VlZWQBSUhBwcABZWZmZmQBGRgAmJmCgoHJyckCMjCB5eT8fH4eHh9Dj4wAsLGZMTCcnJ0NDQ79fXzCDg4qdnQAAMx9ychVubk8/P3d3d++/vy8mJp9/f+Ds7HSUlF+MjJC8vBkMDN+ysg8PD8vLyzMzM3CpqRsbG09PTz9/f7+Pj3I5OWqQkB8ZGZShobDQ0K+MjI+Pj8+lpSYmJm9ZWQA5OUqDgwAADAwJCT8vL49yckdHR6WlpQ8MDCYcHFksLAcHBw0NDX9fX4xpaTV7e3p6ejc3N6ampl9MTLKFhejo6AwGBllCQplyci8vLzMmJp+lpUxMTAAcHJ+fnwAAP1hYWLKysqKioh8fH8fHx6+vr5WVlfPz8wkJCd/f36V8fA4ODkwmJhkTEwAALISEhGdnZxwcHKVSUt3d3V5eXjBWVoxGRkhOThheXkw5OQAAXwQEBEhISJqamhgYGGNjY19fXwAvL3JWVgAAH+/v7wAABry8vHl5edLS0gAAOYCMjAAARisrKyEhITk5OTQ0NDMZGTBcXA9vb729vWBsbDY2NgAAJoCysmCGhhcXF0ZsbICGhu7u7pacnJlMTHCWlrGxsQAWFs/i4kSKim5ubgAjI5C2tldXVygoKCBTU2CAgD4+PnCDgwAPDwAAGVCVlXB2dgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAeAhUBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDiBMrXhy1gOMCDhYaYDhZIYXIBQ46oFCwskIFkRmLHs2SgIDTCBYSQLhaYOuEBjJ7JlhgNoDXCTeTvvlYAVDbB4EXvAwgs0HdD4kLB4AgdWHczB80aBBBIAIDEloXmJ65gOnUBB5g/xeoQIIBAQJjA0AfwXwDzLZbi38PoDx2BRFSKxBw3nd+/hZUlJ8EC+wWkWkCLPAAStAdyNpADXYm20G1QaRehOuh99xpAqRmAAUKWCABANLht1oEC0SAoooEQHZbag2kBkFmFKB3IQARROZAgRUStFqJKCrQQIAPOFChBOgJMGIBCxSgQIoRPUABBARUiaGBD5JY2XyhzfdAftZVh4ADFjzWnJb0/WdAgN51WBB/EvhWwAPmGXdddgJt10B3390m3oj1maeheuy5B19BDjSwZqDnpZcZdO0Z0Oh29xVHpwEO/GmdpBpGKoBxcPo2VouORaZehQ0seBsAFmgoQICvtf922o6nmQfAjcyZt1qPEALQAJIJFiBBqtVVOMFAx/aoHkMO8GflswhyKO201FZr7bXYZqvtttx266221THUmogkNoDfAgo8AAF+CCgr2wKfCjABBQgAiS6TTqYYQYuhCVSjlusZkGOBQJ6or778vuirjDTa+CiOOvI4G4oOhAjAjAD8i+tAGCMJgAPVkctfjhPAmJqTC1+cmcf/ikcWdKdOtuxqpwlUc6w2fzpjqbc+TIEE1e0a361lOuYbAhJM4NhkOLvbkJRUQlvlt1RXbfXVWGddbbiqGQCBAb79elqTqQ7k9LI1+wpsk043OAGHNGu4WtmrtmozrL1mSKuSMj//nKsBQhNkAWcC7W3rxh9DkHN9FjTwdYauLR4Bf/A6oDjkb5925VYwdzfZvwqsZnl6kREgqqwCKDBBaKY+bMCC+xY3tAANkBeBcTWiuuB2sjsK0YALPIvlQ7uiS3Rvy/be8/KQH2902waR6ljzq83c/M15n1bAzi7e+HPQyi+eJ/etr2p2ZTVDYIECFaaNOooLao8+etIbJxYBkn64fIUKcCorBBBwFQQ4g7rEec1hq9rRhwLnI399DQKT+xrYKuSA/B2KeRIhUwOONbyGjGsytLOdkgo3OgVgDG2uql19bleZC4lqIIv6GPUyhp7QJY50tzldzlTHuuVVD3YMzFOB/z7Gw8L5kCCq882/TMccEMotZ9sTCJKSSEOiGbGDWFTKayQwoil5LQLl+Rp6HOc42YBKQxl7IAt9J4ABItFxEKid++rjP5sBUIAEXJzlDnhEBVIgiHY0QO32GMAjEgQBcWwAehCwAOw4MXKQk8DXFMmcODZKSABUYRY3yUmmiEoCzumkKEeZFEm6kZSoTKUqV8nKVrrylbCMpSxnScta2vKWuMylLnfJy4UUqZdOQQDVQglMqfyrmElh0gcwwMxmOvOZzfyAgpAZlcdRUyhnEsgCMHCAbnqzB9DsgTe9GYTwXLMp+9rcOWvygAV8QJoPsMAHxunNDxwiBPgMwSHmSf/PAwRhAcKUlqpW0iwBDLQzHyMcohS6ERVBBDQeOVM2HWK/YFbpoOvEiQUIEIRulpMAK+hnBbhQgZKalKT97AEBlunMD2BKJfx5gLDQ2EBe0WY5EknbRBXSGuRwpGZpcwhOkZIdAjA0ozXZ3gdC6s0KqGAEIiWpSUuKUnqGgJv0HAEGVACik+wIiR9TlKoCh4DqgKlClIpTcQqw0+s0ilEg4tTtIOOcCASIApLa3XfAtJ/+4EiYMTyIWztlnkYJ4GfL4hKj1FpD/qTurwAqSvAIcDmk0qQ2KuhoP/HZzwN8IARSKKkUQsDPcY6AAFDt7CNCMIEAleSwBYkABPv3sAr/xax3IGPViORFL9qETUapKRIXnXSaCHCQXAt6Eosgc6QkLalJykUIymKkMgB4bGRftZeQiFQ66zq3ONCFklAc8CyuWfYl7VFBDoJQgc6OQAVMHWcPQkCAJCSBACEQJz0rEILOypcNGBtJUAVigfM4dlW29VzvQuS4R8aWcgIY3UDSVjPqQqkAeFWa+YyFLOUl78EGqNzlgPpEsQVrWF+KHAcBkKwWVvQnG7USMc+7kvIQQAVeqC8XPqDfcX6gvQeowDNz8M4cQJOZXsiBf0ua2iCogDoiQYAmbSaBx4Avwb2rkPrY5+CBwC9DNqUwempTQRJBoHzaYVqvnGaQL8tv/3FzXFNvcqXh1TTNxUNpwLMARWOV7GcCIWBDHsIQ2gocAqvdrEMOCGBkaX7rj0D+5ge4cN8QhHQEOXjbCzuiOuNEQKbGk2Hgynad3jGx1AMuzuWmOIHq4Ae2zWtkamBrwkfJaTJl453T5kSbVaduAkpM0hNDuELc0c9Xu6vdrjG6kwk8a4h9RokFJuCFrSah0CX9AzdX4AUVTECRqJkIAhiNAaZi4BCipQMBgFwHLwAUJImSYGYQ6bUFBY5JjuwdI/OdautOEj3qkpSKvlZQAg/RhILEWBspQEELejgz1CWIJAW5yEQKG5JehGAbJeUb0TncaREHSr+jPZJ2skGcGP/4w1QrEAaOstYC/brIA8bmhTqkfKotj+8KpPniuUAbJj//ychJDpJxa/YA58Y5AdjA1U1v5M8fIEAYpkqH0nYTA0GXi11lsnWhDJ3oHXnAuuU7aXz+oUpNGkkE9IxfT5g0D5Hu5gdmDPaTfL3uGlnA0ccp5K2a5iTbq1IekrDj+HazAlnHO0nurniLIMDq9OyBS2Nukml/IAdx9zHdS+JThvQcIp9XiEMpYqTHkEeYFjBvRkIvcpo2XiPXWWo/Md3aliiAAirAQGrHuQL8MZskNpWMRF4zVMFunvG3AhZ7AsjWxDck+OlBCvJf/5B2LnPRcV/Bk1VPUAPI3pvvzcH/ol2LEby+zmaaqg9/FFWQek2nr65t7IdSk58CoMf8enWThu5kVsCSP0/zJh1QJld99VgE8WEh53QG9SH2kRmRQh8J8in1lySsEhowFxTTR30MIXZHVwFjF2QEsHkt8QCAllqcdQA7N00yVx9QEoIp8y+ldoAgYgEzEl2rAYOTUQDfBnAsuFzdJWXswyPhZV41w4DkMlzl8V0HqHw5lBAuOB0DAzEfUyCIVAC3s4MJBGzE1noaiBF6t18g5YEi6BJCkns58FTjVE6/B3oZ5jc1A2zh4zvQA4do5RkYZgB11it7Qjpstji3lTYrtmLpUTR+kyVz9DcMxCutgUjr4nWu/9eFEfF4nfUBbOCCOCEeXtBjTRVqE6EuaLY4aSYhD7cqodgjnmhIq7IssdGHkPOHTwRJMFRRC0B5DTRD34NglaGI5PF3jgiJFPEkhnd48LKGMyGJneUFj/gQtIYxBYQxLnOACnZEzpiD6MMZtdaEdWONEuM7E4ZA7UM4uTZlGLQe5kJgBVFAqQhEqpYnntEaEKAuxJgTGeiLb+IFs6cC8UgT29RZddBqvzhJzKhHcWQr0DiKopNI1EgeAJkZC7cqYfSOo9iN+zMZsoUpFSQplOc1+RNI41GLc+RHrSEp7dKO1sUZO0KLOzGP9CgQxtVMPRYC4qgTyqSJ3ZQDMRkTov+CNLakkivZACpAAH+wT920AnAIFPI0AuBUbgfwXqzXEvsGNjuZjCspXVUydSPVXnM3FAaAAfZ0du0VBJWFEMAzlQfBk75IJSFgUklQAUFQfDlBXlLVcu3FBv83EFAjPGT5JlKZlwNhAUzndhUgBQTwCCrQlAIhJWPYEhSwliWVcz1QlM0COFITLdPCfa9nlhqoOkEAdyVFB1flluOGB1qQdjMROtjmmQcQAoRzl5O5ciZ1CQIxAthiHPbXLoaZS5hJfRQQAkHAmC23VZZJEGJnAwmQAJqwlwihAM3hdBthAHRgUoI5AoQZc8CDlwkhm9RiUiMQm/wVApGAdpxym7H/lJuN5wAq8AhXqW4VoAh8lhACgAfFmQAlgJztp2dEQAQEECPMeRHjZpUVsJZItxwaJIgcMQIjwAgVsJ0AIJuMYKBRyZcIsZVylwdL9Qj+uBACUALxOZ/PtwBaYANLUJxLYAP4uYcbMW50EFooNQIfkI8nIZuSMlmREALnoaD2J1PBiUXkiXePl1orAGTI2BAZuqH0WR8TQAbxmaQJsARkUJQa4ZMEcAylhXg54RjCpKAj0J1cQAATwCmfkkU7CnZiF4wH8Jj7aRANgKTFyaEL0QBEoKRwSgQ3KSAT0AMVoIlZSRSXMAKTwGR5IoG7EaZEJwBK1k9eUJcJMQGgEJ9E/5CYJEIIIQqnSboEhOCiM2dQDCEA9khPGFCkQTECrkBf+ANKZzoYgkpyAoBom+gQDkAI8bkETKQQDUCckqqkbJoQYocHeGCJCQGMnOqpepqlLWeih3Gq0Zaq/ZSnDGEBb1qcNjCnAxE6kVqrRIqh8JkANsCrCIEAm+pNnVoVstCgsakGKNkX0wOhBIGsfOd8ZamhxdmoC4EAzUqt1aoQCKAF8ZmtiRk6u3cAOQCsTDECG8QFimSF6FoYjxcEdVBPjpqu7gqrpWod80qv8lmkC6Cm2GpOCdEAHaixW0EmEiCq2CGeVPEYVghROyV8BEEcfLlR3aYCIaAI7NquzuqW0v9KsWtapGJHCvGJB8gpdgkaAj+JqFyxpwkamwgQsVIRLZDBGfPYOZRBstSkTEylaB7bEPJanKRwtQiRpjibAD7bEMxarwghdjcWAiOQglJ7FSPAWlWmFbgBJkpiHpExgcXBHa5xHYSjHvhnM4IEMgvgMYOqCMnasEhEAJFKBjN7mARAq9SarS5aH4ibswpBqCtgeIoAsFlxCQIQCfCSo04hPb1DO6CRLDu4IityGxAXIOqRXCnSOB/zACZUJmCnruMUAoZLELMan1rQsOPmuHCqrw+xuwlABtC6Hqp6dZq7FcLCBSGgPVMRLaM7KEtDYK6CN71zKm2ISGPCjUS3AJn/d1pKaxD3Srb22rhwugREMAGROxBemwCgQKDtB3lBtrhioZx+urQ31TyrOD+gyI49c4raCy/j2GfGyHfHmxALoAklUAK+AKzjRgaROqKEUI4QoajxSQjlqk2Z51m5SxYHKgtPgRvtU0MtVjiX81KtQQGsa3/WOCMVAzDnN6hY9aPKOxH2xyFSKx0EcJ/52b4E0apJSgREO2HJi3TLGxbbgT+M0BQkDEKNBJG80kaFdBteo1axgXBlFHBnZmZuSU3I2ns7Bk5JjBHKmbQUYQG+kKS3WpbcVFLeWsZhoZwLEAkffLBYgaz4VAF/cFVy7BI7a74Gkaoe+IHfaheMFAlN/4zHY4GsKuB2npB7f+wSFOCuFVu5lRgGOYfE7XfHYpHIk8DIYZGqdcCZFZAHzzsU78m7iSkAQNmZ/XXIAzFunvzJoSzKX5GqvamWKjDJHnHGSit2SKq4GIpfooVasjzL2ioXk7DIuJwVhMyY//kBvpwQCFAjaMwQUtbDJZrNB9FOWsC1g2zMJbWWyazMtTwW7bQAtzwVLYADaOAC8jzP9FzP9IwD+IwDdZeqpxVagvmvHgHODVyirMckHzrBJJqfrGcBLurKaVnOQiaVtIzICxACoBsU7xzPXyAETBAAHv3RIB3SIj3SHy0EJi0E84zP16THz4lP54wRETypJeB8qv+DsUrKpE46EQ59zFq1lxNdF/thGuNrE++cBRvd0SSd1Eq91Eq9A0JAAy6AAjhgBboUxgQwxi9tEcMpqb17EG5KsXJqEa6Mbt3Jyda8zHJxCSGWzilhBfFMA0PA1HI913Sd1EwgBF+AAi1AS+pqw2atEassqc9qEA8AqRRLqUA8yF4waWP819uK1nKhBva7EkaAAhu9A3Wd2Zq92R9NA3o9nkec1RUxpJIKsQVBvBTbxhGBrHB8w/HK1mWxAM7sEkaQBUCA1Jyd27qd2Z69161ku3H8U5Ycp8R0szir2hAB3K7tEA+Q2GXxAO2sErVNA5i929Z93XXd26uk3I6NEaT/Ldg/l7Vfi9zKeMQAXX2NdNHDM93Vjd3u/d5yrd2kdMCruhHfzdWhJN7H/cfK3XvOHdQGKBcOGhLsDd8GfuDxjQJULUrgW7j2PdzBC23Gndr8nbwYcFQPEQEhdoFxgQBh4BFWkAXUjeAkXuJLzQRZsOBZRN/L7d0QDqddLRCoTa/k7RDKLdrMjYfftrZfEToijBEtgAJAENcmXuRGTtJD8AVGkEVfmGhBEKSwN7GSequFPa21itgUURvJq6wWQSY8/hUNMNsSgQZfgNtHfuZoDtJDAARoMDxilwNCi2O8mBETPuU09dX0GtYU4U7V1kwy+xEFQLtq4eESYQQuIARp/57oih7SOwAEn00ab76w/jTZwwu8MF7cR3rlTTrUgsVjzbRoH7YRwkIlECABHE4WoaMMDRHkI77orv7qHi3fi8HiXM6f+FqrNpB1Bg2iIprQxJpTyXveIhHoG7TjZBHmC4EGNADrzN7sjb7kiqHcVLoRF1urMU6+9tnNnO6eFl7NEOHleVJWX1EACmoQOAAE7d3s6g7rTPDohsHdta7V6KukxPwZy0nnCxCMOA58GzRAXx4VRvAFRL7uBO/sQADthMHdRLnt2jzvzirOIqGp/bTvJoFhELCD0JsVIW7mBd/xzd7uvh0YB5yUK6CaHBGaDbyrsD0RxiXp40TxKPEfGf8f6P/+E1aAAoju8SFtAiLgAxrw80Af9EL/8z4gAiag89f97ILR4J51T3lQiTVftgKVEg3AUpoI8y8x6pRl6lFfEzhQ5kgfACaQAkcAAi9QJVTAAm2QAWzf9m7/9m3AAlRQJS8AAkeQAjwQ9pzd7oDxAB+QpVIlBfdF6TzhHagslN3Eos7tEoEuSVtPmx1yrh6h3g5x862u82NfAwQQBRmQBjAwBQMQ+qI/+qRf+qE/BTCQBhkQBXbwAkcgAnqv2TvgAiG/F1v5n1N1dt5+EMp5LYuvECR4bVQFZBjwxThB838ao+B5Hl0/EAuwAKlHEV/P8R2f+ZtfBaBv+tq//dv/DwNtQAUnUAMpcPSxT9cHzxfmWQcEgG34RAAbTBE8TAQNPP/zr/IbQQEqp5btNZ2NARAFEAgoAABAAQEJFS4saFAAggINDRKgSKABAoMZNW5sgYLGjgAhRY4kWdLkSZQpR5pIUYNAlCpTBsykWdPmTZw5a26pQuXEDx0qhQ4lWlSlEDQblS5l2tTpU6hRpU6NSiFECDoVtIbAgMEAVagICJBZksDsWbRaMIJlqmBCCK0VpBAYcSAEBbZ59e59inDh34YRBBgwsIDiAgMVK06Q4IBpRxpFU/AwWlmlD5cwZerk3NkzzTWB7LzwYdn0adNDsrTg29r1a9hucxAIsxXD/4EPFmA/IGAD7W+zZBbABkCBAFytdEIc6DFBAXHo0WEXsKDYOgTdBiFX5lHjhIwjpVFzB2Em5mf06XVOqWIGBOXx8eWX3PHFinT8+WFbYFOBwJ8QIrmtuQhcc8s34NAig4AHYHNABQyS0CoMAlY4gI3s9NNwQ6YKsA6xhwrabjwRjniBgBrcCGo+k0zQgIAMNlNvRpvsiGKONTqbIgMCNDCBRSDlowEHDos0cikIglihKwx6OOCAHBpwrQEifrOhBCyx1GKBBmEzAIMRCJCCDgIqOCAICI5UU8MCGhDgAYkAGBFIHlL44bsffPgRSB9kYGELGgO1STEzAqkC0Jy2YP9BBvGCdNQ0JlBYc1L9ClChriczHUGFLvV6gJCyzLJhy7/W2u2DukLI4wMLN42TUlijQwOIR0vSQYMTQdBgRZJ4EKGoI+xIw6YMijX2WGSTVXZZY62riIo2hsUpDTuOqPVao4aQNFZuW2sgh0zDrWC4vQQowSxStjQVP7csPGAFM5+Mslt6WzPiC5CwbdGHH2T4KYU9A3jxh4BP4uEFKhCtiVmGG2bWWYpYyCDHRKl4AT59Mz5J23o7liqCCeoIN9PcytUkARsIyFC/BpYb+YA6JijQY5qfsiKLITQWSgc3QCDghSNEOJGAE9xASYQT2hB06ZsUg1baz9o44Vedqx7/ieOas9ZIAC9efpdBvQpYQAsC1s3vgUu99kIArds2yAoUhLDaKB+OkMG6F6he6YQqmPabpkIPDbSKEwqWzwQREhcJ8T11CFgEwx3F2m2PFVjA3XB7YIPtvRDo9OzBbns5iAWeo9xjI1xgYu7TUoD4B4wDqCGKv2v/O4oaghRBBg3spgzpH0ICgWodetR48tO7ReCDkTf9gEu3xcrBC3Azf/7V5CmdNWfWUfsBYqI1CMkHO2S0/fwZp7Cj0aI08AGEI0z4YfgARAAhpCPEt/+9AOgP4AcNyKBqyMsepRYguidd5QAVUEEDTEczsZipByoIAaZww7kCTsoIWYhM9+Sj/wMRaECEIxxhaWowh5rAQIUrRB9ozIeTNbwQPXPIXWUIkALZ1YAHOhCg/UJSAxzaTwTB81/hXsCr46GANRlck9g+0JUcpO0AIwjBBMzGLQcYgFWaYgOEMKAIcjGRQy1Agwvk5sG5nYBiMykWCySWgRbOpA1rrAkLYCBHOqZnDSewDAFCIsKQ+BFpIABPSHz4HvphJgBusNbcdgAEI4hRTQMRQJlGtgICLOCKa1IABSBkwSdh0gAJwZ4kYdMRIHDPJB5gJbaw8IQAcOAksgySDuyAk2LNpAprmAMMquBGOA6gCmmIQhQAtYYoSGwmaWBBFIaVgS1AU3AZYKbStlAoOP8KDgbFvOMAqMmCQOjEDkgcih8FJr4ACPJ+GqihD4dIv36B4AUC9KBqlmjKDS1vZD34ABeSkMmVqckCb3mE13CzSXy6BgdAyFdKSBADEpwkBvLhgAcCMFGTYJRFIpgdLoPJAjNkQIUygckAWNCGKcwhnHaIIQrTQIUp8GQABJCYou5IgGHdaApU6KVJYXDNLQB1pn0rKU6iYDSjmBOQ6azf/WSnP6cS8leFC8kR0RgSGiQlofnRZ7gwcAitjCmTCM1PASBAAEWAUlxh3KprrOACVQ4Fo1AQAwk48IYAeACiYggACaDgVyxwgAN9CMkTrnDXANygDByIaCwtOtFW9jX/JBOFwmKvAEu6eqCx7XuJR2dix5lEE6RwBC0MWDAAM7QBBiSF2kxpAloCzMS0Pv0sDOYQzAygMLbeDOZNjmrDP6JTnSExwQtS4MP6EUAEigwJI68qkiHYp63RWUAQvIocrSRBBc8jK3Ei0ACKJOGfIcAcybo73acYAQdmNA1GPXAGD9zgDFCAQgw8AMsYMBYKhJUvfc/whBvgtQkWxUJEK3rRvjYWo5SF5RPOkNdEXGGzRNFAHG55k1zS9prPJO0dZ5vSKJQPtDTZLW13O9sR2zHDudxthm9iB3Q+V8YiEcK20Nsa3lj3SRj4Q1zkkgd4cTc/ChDABAhABymENQ/x/8oU6W4cFSus9wtCiOtp3EvLA2tUox4IbCI88AYsiMTBJCDBYh2LYDJPVs0BEMNiIUvLymhADgTII29rOwAYUGEmgegwnk/bTSrAIAPhHECOSgxbOaKQBdKy4xr0bFJDs7G3NVkDAdg34xkPwQX3fDJbHrCALU4wCUmeEPMWKGTofFoFtPFxGEydKf98rtMGSR0QzuioK4ckyyLBaB+aAMuKpjkkHhgwK4H92ASveaJYKAMUEOwBOBtFA0iIAwqJ9dFuBoIKzezzbKNABWgNYAraVuahb8oCKgRCJi89LWgzAO5gtnjSNJmDcjF9b5HU5z6zZgsCFuCFOlAxD2Eg9f+SYf08WetFAQ1QwZJ6HBcpADlTdfAC9PitkTnhethYfuwN1kyCMN+g2A8OAIATAcuSn3miYA5AfdU82Ja/2TTTloMZ4oieEp/PDASIHb7vDcmLU4XIE8jBCFYQAgIkgQtbDFcQyoYACzhmKpRMyFvqggHsViAJLhtBDiYggAcGHeMeCRIH8ptXjve1CWHGqMg5cIUBq/3tJW8CB5pgYGTLlwNYWHDJz7B3mVtm2nwgQN9u3pmc164KFPF542lMJLFH5bsqsO4ItGLQ2XwgBCqYgJv+8nkBgBoDbCAA0w+AgUhcJQR/SFsQGjizyD8GBVOusuNZN20G1Pzwu8+JGe7/wEfU9Nz2QCJg7JdiVjY4yaCnV8TEgzD68P6TAF5gEgbixcB9Vr9JmoNAKY3fFPWyd/hVw/0Yqs179M9kDnHgg1NNo4MTXHr8LNI0p7+/kYGGoKBe68rI/IPksAqBVxuZD2Cyl3mEKgqo+5uKt6q9+QsS3GMAQ4gDpUm/w2uDODCE9juN4mqkB3yUR9q3BdSITvqkl+k/WGM1H6sALjDAg/OaEcAAFaCAsBtBtliohvpAFolABhCEO0gY24qCQrFAv9kCKrgDQWAAJIixypgfHdSXIbFBjciiAiRABFogFfSxFjQoAtCxgzMAqZNCvsg4nbkBlLOMaDMNN5ADBpBA/1g4BeuYNyJUD/awg0Jow9xDqspwA6p6Qn1hAsgTw097oq5QBLTyvyMjNSkQQIMKAiPLASZBODGEDjLElicIs/aKDx2IA0EAHyqoszn0jNCwg03gAzxkgDggp6EoHlX0Q0eJwkk0CKpLCFArr6NLuvFSvpFxugd4gIU4r1jUi0qUD8NirJbjqxuwKyzgK7qyK7wKgMCCOQRTLA4oA4+rjBPABDhUjDgoBIqgAsMLxc54KYpAgjE4RUwAPqMwgaJxxWuhASUKRqeoDkisvhz4gA+oR+3DAEmURyMZxtM4uQBDO2iMKDGQpfeKr/kKAP5ayIm6ArzqgzMsihqABSTgRv9M6EFEoAjzEMdEYQGKQIQkPEUGgIUaMgoQCB53DBJ4tD9/XApfBD2ZTAhgfEn82J74OAMsiC+CTASPgzaCPDMu4wAvQ7AyuII+cDbL+J5N2EgCQMJT5IM5I4CO9MiZ2BGKuANTJEkGMD/5UwkTiZyVNI2WtEmqiMmEM0vUUZ3TCLAr8EmgzDWgdCxfOzYEY7MyKErJkAEZAAE56MQ7OEeuHIM9mDPzkCHe4wkziINTyEiubEM5OEmi8IETQCJWukyLOo1LVAn68qCyVMup4A08wIOyAU23gZtbI4rMLDZZirs+QEiOA7nEijvICokCI4oU4EscYsc94APBfMw2JMz/OdMM3oOBNqCCOJCDPfjNx9yDPiQK+Ls0MhMsYTONuSQJYRMDvrKazzTNqRAAPBCV0vTOtrkZBzQJuFs7gnyCJriCwwrKinI7uEM2Eqg7DrjGlMhNGcAhkUCaOwTOwSzMl6Cm1fKbKYCBNMiAELuDQjAEAD3FQpiadQSak8jOJ3gDDzhIY2SzPnBPZyvGiAJKDzgsa4wl/WqlyuKA7RSDDr0CpYyP7iTP7zwZ8azJ+3OAhEhLAPgKB8ALTzEAH92Le8nBorjGNqsV/eTPXnkBqHxQkiTMQkCEO/jGk3IYY2kDdMtKRCiEPRhJJ+3BO7iYJnS/khA2DjgDEmAlj7sC/77auwArgwAQSLwCyidwtjeA0zIog/hKM/i6ATaNJSx40/GoMZeUUakQGy1gBvHUURscDDiRAAzSCAI4iK/IiwgonRrci1mpDDH4u/t0lCQFS/b7UgAdAw1EgiidUvBpykJAAj4wBOYk1TbkgzjwwKLgQ7EMCTPNzL86U7wjSJ3kSaB0y7pLtgR7AloaUaFMQ6KILhE01HLRgrMoASmRRwdgq+dwgAYwgC6Z1AKo1IwYjAZwDM6JiIMQiIFYAIJAAMLgHAWQACB9jsGQgExVihYwBoC5qlAdij4RSVklVVPlAyRAAkNwzH8FTkFABEaxDFZ0qMY6MCg4A8JKswMb1v83eMsbAMomeIOMlSVhI7O5BMqKZVaVyCpoJY4FQBBQmAB/FIAgNYgIgIAIUAADKAhvBVcAsAApcYAGmVQASIifnQAKQAAE6L4IKIDnuAgAgACMeIAeZZsHwNmmaABL+Am9qZp9LQoXIQBzPFiv/dpTHIOL9JGi2KEAYEc9rNCHtShiC4ky+FURDQnWvCiPO8i+wsQ088m+wquRbdbVOFnoMJezIIQwnESg1QgLGKXBYJub1YiiRQCp81mgPdxvhdnBUFcHSJOM+LqE8NmnIAAlUIJdsAQZcAPhe5SstQweAIFNWE6wfd0vJcxN4B+juJMUSEmh2FW3rTsJW9YASM//MAPKTq1GWYKCunuCNPO1JijRvk2JR4okwI0OwTULIlBAG0SAag1XCYiIAiiQxtWIAqAAdQUAyWUbyv2KS20QUsJZAuBe79OIB8iEC5jfC+iFT0ARJQVV3ZwPzCAA5YxV2H1dbYwD0rAMdqSI5xxLkYiUQo1e15jeBCiBSBVDtwgMOCkdg3CM783g54haAHAOAIDUny3XrzArg4BUtygQBYgAA8iOwmUKCWAD+r2AWlADUdCFTDiBI2jF1tnfIGEJl/jfAP5aQdiD3wOK1lGMF8jVJwSCQHRg6YBgCfZHbYUAwiiIojUACOhZSoVfK4YAx7AAxHCTETaIyg1hKybj/wewYgOY2QaAAAjI3qZYgGyYYVswiFAABFfYhVR4ATdg4qHgAR++FiD2X9cd4gc1hEL4PSACZKG4G8VIWz/cARd4ViiO4nMxiym+5I5xAEuY4VZQikGgBU9gBQLIE9TI34wpZDlwVVgd4oBFAjkg4KCZDxFQDAl1x0jh5A2R4gnmZVgRgE+YYUBwimCoBtI9gtN1PJY4AnnS0lYdWGmeZmpOVYp4AfiZjCBxCYoAAUd2PCcG5l7O5Aj+ZXFeEwjohRkehKdQgwvghU9IBf8Zn3wdP8TxARLKZ30WIR+AHGzhgYpgwg+kZEs+Z0yeVnM26CKJAAKY4VqACkegX1WwBP9cYKiQkIETaWQF9qAXyWUdrDGF5hAIVouQnhQEyARVoF9aeApJmGFeIJeO+AUBKmQQ+MqNxpYTENMP1LSCLmnpQABpTQDh8OkyLpI2IQBWgABHqIR2nmFWiNQFwIUsWJ2zPQFVvmlsSQFbHb5HemKi1pAF0ATSZNQRFADBmFl4dVd4pcGfNQB6PYgHgFfHaNeZXdzniACIMF8DGNfWiAALgABXgGj6VQIQlsUwupdroCes1phvljFC/eojQYihtUkCGKWYLQgKYBumBQCnzWzO/orBUAAHYFkJ2N53NV8JOIjOEwCdBQCeNZKWpt9PSO2M0KSNWABtsOi5SRx/Hg//HbCWFLjqxR4KnoZs46YKn73WhJBrzTUIzq2koq7Zw2VZ5+5iAHjcF9YQd55fVUgF2PO3jQBvg0CDDtKZHgkgHiYKH1qq4R6Krj5u+J4KnzUr7nWAM54I941uv5iIjNjg8B3fIono+WUDObZtjTDwjOiIbtAYc3ofgeEBDeABHpgf/pQf+DEBF9GVH1lv8bldXQmJCdeVX7FwdEoBzNChJ2Tg+KYUBSDaepVCn3ULqXOAFAaAFW7hDC5jt/hZH22ABmkT66bxzy6SScgEXVCCC7AEiRDvjGDyjRiEZUAGU8AWc2qJdNIVQYYcIAoA4woAH9ABABKY4OHw+vmRLc+b//8RHzTPn/6JHzdQyfF73hWflBYHr9C1CBsVO8/NXC2GWjZ2YziWktDT4gaJWTDMIsJwjDNeYy3Obq4Cr0xobgBAcIOgdIMYhO2e31IYhSl3lB6xm6AwJx1wKo7SgRcYCXXkIzKHcELalVM/Jx4SISekH+SyPRWfczU5aiUogi4oAl4vAjBYgPeV0cPNnhZfcra67mQHgFWYYWff9E6fD+XSG3NCLiEiU3NiKg4X5NIQIeTy9rxJnKCgdTK9NznHdU6aAD/ogg4AdjiAAzAogg7wg8LmC7yWgGW/uGKXJEu39Nh2doCHdvnI9kASCarSgD8+Acowge4oDY5qqnMSmv+QACB2/JH8YccVGfdfqXVMu3XvHHaqkNojaQAl6ABIAAM4aIQN2IBGgHdIUAI5BosHoICzqgh075x6V/aNqAQBB3ifv4BNjwZgOA2CZ6rxeYEXIBgvx+b3GHUQAIGgIPMfwOYa6PAXqIEPN3V5Eh9yx7Rzd+03MU3PbY2xZ4t9D009YHcwcIKVb/sNcAIw6AI9IGulwNHEgBiZnBm/kMmG2HvQ6/uZJAgzDnzAn8nC5/vBN/zER/yDIPxwnUnYy4ioxfPnsHRA+HnMn99WCAVoKIbU9Lk9+QHh9jkaoIZkaFoDmIDO67wXn0TPhRMzVt+opUF4LQi8Hoy1YBC3hln/eF2LdwVSwQhXmrXs30/ojRCAGWh3OHB7t4cDX4/5p5j5mneWvF/8v7f+zzv86298xed+xvf77Md+wBB/hiB/hZCIwI98EsReAoCAZb98gO8EQJj/+e8En3eGjECDL6DqewOIHy9eHAlg8CDChAoXMmzoMMAOIM28GSDQYMGCBgQQAACgoMEEjh1Hkixp8iTKlCpXsmyJksDIBwY6GngAYCOABg0iOFgAoMACBwqC3uTYgOOCAh85QuD4wAGEAj8hAJAgQWlUABQEsBQwowOYRhvGkh3rZEYXAgpckoyAQMICAnJhsq1r9y7evHr3rlSAwGZJQBcGE1ZzUg3hxKtK/7ZAAWTIw8iSJ1OubHnhECDYDEyYUHEBRwRxF6ztiAAn39SqVdPtuCBCBJ83OwrgOrvATAC1Z+sW4CB3gQZQSb6tynF3z9oScqv0WgRO2ehnOygRmdeBBZCrt3Pv7r37oMQXOqXsJH7wIJRWstDYcbmhCBHv59NvOOSLkY4PUFsgMAE0AP1RNdJp1n134HetBSgBBRZ0RNdut+W2G4QC4NYRbheSNIEDE9DGVQFRFVCAA13N8Fx0ZU1XHYItuvgiWxM0YEGJMAKAGGHpoRTeeYatZAR77tWngQb1GUkfE1lYYZIFpHUkAQQWTLDWaRIQh5qNWdql4FBO8hYhTBpCUP9ihQBMqZsFCkwQgUdsCrCAbQJQ4BGHHdXY3FdhpWgWWmpp+Seg3s1FwAISIMBmizxe4GNKOIqnY0tAtvcekUdaKhkTQKCwZEpQjgSBBDqZRoCDI1EwZ6CpvmQAqxwxOFKZt3kGgW1lPgABqGvdyiqbEfgJQAQQGOAAVAbQamIHKO4JRxFFNJBSbdFKOy211Vp7LbbZarstt916i+2gg0JAAWDf4SjJSoomhu5dkgopWaWXyntQplngUBeoHQ0lwASAUUDqSBGqOnBKr7GkoV7F8fWAHl2A5USKToDRhR7lmvQtxhlrvDHHHU8b7lwG+FbXiGxV0oojLTlKWCV8Aen/ghBCOBTvvPXVe29eQ5Xa4bi0QYDRcbYRPDRxVh7MXF4Gp9aAEh1AAgYcTkjtBBxgQKLEs0RrvTVJ4pLrksW91RUKoyqtfIE03xmBQxYuACEEZDTXPBkTQnxh73YdloqAZ2vtJtoCInM9OOEpqemHw0XMsPiJHfhxZuGRB1rooXbJFrDQLrXMkiPiLWajAMKg4cIXQjAx90E7CEGDCyjgwOmBgB/X2QMCS0BA5nVhd20BiEr+O17BEaBEEQ530EURYCQFPPOSn1bah97ZIp4jm8Mo8Egt4DB66afTHbPdLriAA87cIbBVbTSeBLjI6AstAO4t+RUtSIMaIIG0y8l1/79Uzfuvkl80ogQlWMRA/zvgwNREgP5FrztnYxfocpcS7Y1OfGggHw5a8KLzRQsj0gKJjNRHkttNK2DxSwl2NAIyAzRAAPojwP3KFYEChAqBNjSJXxAAvRvy8E/wWyBJsKcadS3KhxLk2vniMpeMTGBcDExhZwwgEviVkDYnLElwOhM4abGKAgYYjQEogIACUABy+vpVD9NoFwUwUCVt3AsCDLgSCpQIaSVBlRrlNwG5tFGIqTHPYBwBwSz5UWuiIRT9/kOBEVEAAp6xmAPgdxzcScuERxSAcMSGOZI4gIZZExVJjpLHUbakP2+E1UjsiJJCBvGIKTGAVBREkgfgkf+U0JpLH12Zl1AAopeAsJ6WWDkwwFEAaMSJyyPdMoFaAqBAVKxkR/51yThlzo8K8JOaLCZMW5ISTkYDgEwa8IAC4O44AUIUAjrZgPuthVUCcBM7gbUcwXFynQ5SwHJsA8vZ4DOeVfEdN3G4Rz62MqDbTJXsmmnMkfSHM3MKFgQAehoIUBJ9ozrWxahZUJOIUje1PGhAewgVNekHAgpwi69INBsJlGpNDmCTBaxkFaVsBZwzyQr+2hIUBTgoKzXdJ0xmBM4SKWBAIb3YoAwEUgQuNVAJ7Y+BTiMAXLGpjCJUqH9klFNnTrOBXt0o9pp61AM2KCc2EWfXUNmTZlqJpw3/EJYmJxAtAgxHkx2xAB6T48KZALUq4kSnHI/qq0FVU5c8FGugoNpMLC0WrxOgkUw6M6MCNBGGIKxI0E4SobB21a6eHesoFyCsQgFgn6h8EE2CI5UosXEmYBoRbCdU2JGECLZ1jKVpJDCB1e4QtDRU4hV/cko1ItapOCnQMTPCmRAiIDtyWcCZXCiAKXaWs5rV6CZBS8q6ktSFdrpJaeiCgC8+iEquRZUBdqamtdSUtrIRSp0AcNvbRPOd39TuSK5Zu8Bys7jGDY2Mdii7AmQnirtt4VcLudlqMrOB1nVJybTUO9oCNEsN/lNZOyJOfAqLK1OdU2tCYprALQdYwhLK/1sh8CwEqBjBQRTWs4p1rL5OlVUKEEDY8CsT/GYXeHxrgAI+8tg7NbMiUpSvBWyy4I2WJEKnym+/rptgV0a4xzaCIYaCux1ZloSWPHaRUb/8WeGG1L+pEjJkl3tkfSXUwbO92JyQq+GsZXTKJImwEM28FwJcpSo5vbHI1lKAByynf+OVAKIcYM9xYmic5ZTvOsuF6L3Ublo51q4CLq3dmnC0VP01LOEi65l0NglABPKgAFgllbBKoLfZlHMkzdhk7Nr5s3rWC1130kKu5NS7qeaJTxAAZKAAa6dJzk1NUvrSiCpgn0XVy0f0sDhrDArIYr5213prJiKT8tYDw44xAf8nrQJwsCIebjVtHSmBO4HkX7QCIVpXSWvPLpnJVy4tLHfjoY54CEw56d+w8EqS18QGtQESWaq5Ese8UFYJXeiCEmYxNU74Z7jYHutaS9Kho3p7aOJ+EwwTbsmpTGDd+voXAVS8R8+g76rQmveD8wxqQf3EtVxpDUz8bdp8Zy6mGYbQVUbEJpMmzQ9O00MsUFGWRhCqRQ64cF7ON0PYThictalRJ0fE7YVrNztMovOn88hBkQsMKCUvkQN0q+JwyYi/K6l3rWX+JwXtBq3B0SRMBD6Un7zXIxgJr6C99NL71gUBYDieHsSSIqa7PTUIU4lpDWfSAtSGklixEKG5cr//2hhwm4+3YTY7zfGZH3A3rFY7vKXl8rvAnd7zHrOL6M6V37CqRP7mMAQAU+OsvcpncRZW7nGclwYYXQmx2NNYOAH25sgEVaRWSsLXAuh1klk3+loOHQvFFZlwOogGag1LSdJOi7twOTUKp+3h1LvlZNJ/oCxJfA1K+v+ZfrZ+Wb1qWh/z3HV8a0pTSZjZRb9QwiwoHfI5wb6xBAGclYN8kYX0mpXU1HjhXUc0BTiFiAWQCGm4RUkEYIhpW3qNSG9hkgJs3AMAWWz4RVTABtpdDvA8gKzZSQLKX9g9GILo35vJndgR3klk2nXoQQfMAMQg3wY4AV21BF1ciGkloIec/8mF+FtdpRawPNYp2RHOmUarlBb+vBPtzUmEwFIDbGFSIMxbVETzhB6TqFK3zZ//1J+9fQcOghX/seHFlYQFNI0QEmERAowCYghf9c8VJqHNodbjmVYE1FhJWOFIEEX0RN6spVYIiqCGUMCkcVnhvF9JmFqZ0eHAUJ62sEpMvdkNwlwOzmEd4gUC4CEx6CHFNd5plZVp2d2zZMWOCZyv0AmbnBSnwYZHyJIimgbRiY0jFlR3Zc1JhQhN2MQtNhO3bQ0MaptCgVb/HYgnRktFgIxcyEhtsErqbSMnsh4pyuEjBhTXbcc1dcHTwEEu7AnToZFKwFCulFb/0N6wyJeKlf/YUIQRXeyKAUTArgSLsRhQn50WFnKjVAxjwARO7kUT8LFJq/SEPvJbhWkNGprEA2jaKE0jd3jiNWLjXGgjvLnT/VjAuLlIHGaXDoZddzRAEXRAsiCdAY7FLRDAMCxfSlhilkSAGv6JokVOGJ0i7A1MwrmTNSJcIoHkHiGcxY1irblZSQhVMDVfP0lFBLDf+bGQkh0ibCyHSPyFTvgNJe5TVbJQjRyabSha963P4bkkxEmc1FQNJYCBKxJkqlAiwTAa4VhAMFokRmbkN5qkh4kiJ5FktCwlYDalJkHlSMTflRnFTqwVT8iXT9zKSXFEyMWGUojST3rdr0FmC4ITCsL/RLBEQLMt5QIYnUt2ACUwTkv6gQsCZR45wBGihCaO3uC4oZURjv4ZpQWkF78R2cbNXQOJl/6YVVrJF3A8i2nlXK3klhnGW94hHD2dRMMZT2oejxLsFmySUlF5mkmIBn5p5HbgJm3wINdsFsLRSDVikn80gDR9kE2+SKzABCWyCUw4oiD6oTyilr/V52wsp24EXdWhRLQxDuPogbW5xNSxiVCUxEkZTjPK13SZxCFaQIWxUYRhqFKIHwIIgIViCGxNZBp5keHUpm2e57nN0kLppnQuwFZ0o5xYxB7RyrQY5oHMZ2kpY84ZDZkspt80oFScIAXuIn1yxTXxXWlEaJdR/0tfUqeq7SdtTaeDwlWTNUCVYUjuicYOAYWcTB6cfJidgAa5AVVh2hLfQCNt7KRKbo13PcCKKtSXch6a/sl6asSu1c9c0KiFEA2OQuS/eASUCE5r3Eo8GkvtUaCfwkSzRWQzAV+Tjqc+9ZGUhhKJ6tQqoVcbTaKFMEdOMaK+8AY3ydlJRIB2hudftoibAsjHcR5eRYu6KamqzE+12OgoISQAdUTBpcoXvlEhGcrn9eY6GVBsSMCO3VlusBTCkGoUdg1skZKonoRVfJl4mg+qjUZtvOpIpF0TzeV2aomtopBCwuqL7Oo4Fk3NNVmrFVUbKRqhGcCWetPkIc0C5YYX1f8jJZ3q4DyrSVCWiG6i87iPMWmrBbJZ4NBqtx7sy0nhG+KbsSyTOI5EvGUYlqrUueJqRM1gXzkrY53EpEojvgJKQvlFweYXv0wawp6sS5Ark0WAd2oIy0pmMv6ETeRUThjI42lIUc3sN2Usbcypj23sd3oJj00rjIRsyfpOVcqVz6LsySaUof7kFwXOXd2XhsQUMP5kzXrEW2FtlN6ZZxgLYAAaq1Ritr7m/+jrSVzklwGXfyBQQiWtAEAPbizAozKt3apE+3GUkprtgViAd54t0G7n7cxFfDJPQs2txdDs3S5uXUCdVqDEy17P0hYO38yl2orZaczF3x4Q4MysYDL/LuiGrnfolrjiapSJ2WDJRekyT699rui+LuzexUfsJQA67lhRVNMxD4EpKXkGZexi24KymYciCtUhyoOi0J0QS0xcnUc0a371q50kb43Mz4dO3fR2qEgo2uR+R1El6BwF4JehnHkOze7S1mV1XmAu7O9eHG7sU0+M0XjFUpnihmFxhvR5Bk1chUyMCJw0kqB1LEnYL53MRLBYCHgmXBgGSAb2HkkCSoeM73euSR3uR+Cqyu5m0ahla6lZR+8S7fraUIR4qkeAaprW71aVmNXml6bqBgCn0gnPREeNcIRkhX7QGe1ukIi1BNqKmVxAb6BgsBSBW23KziGmL8Ry6wdL/879ra682eNJLFCVbRMs+URU8FXYaEj4+a48UvGFuKMmMSIm3YnwwQjiusQOi5mxRI4QhwbQ+M54RVFwWMc1bW8Sh5oAKYEeyEjdFtQkHuq95mYiUp7IKOEbcSmUlIYUC/KmknAJ3w9tPRmGfKyCggQbnrGYyYmPtfEbO9GnvFXIKUfh1vHvnAbiuCQk+MEMVHATk2oA41a5cqxSkMaFZHG6UexXmQQsDUVrAYAIB+iAEiTltYgC/AsF0PFiITFoOcAeE8wmLxIZOVILEUBYdmiZ3gVpmkSDrkYJivJ3EkBLpuYMiEKyqHKd+VkquTKTDVogdy1QEG8nqVLZhU3kPf9hgjoI9vQPsZkGMrOejPjw+uwzN3fHM2sjXKRcbRhsSXglUbnpKdGRlNnF023NgP7ydji0mqKiN19nEBIAJYwztxotq9yPfSYiRuRGDCtsxfLjTnxe1Jq0Ac3zhAiLI4cV8N1JP36HaHwrSlxpQA+MW5QkXjSb2Bzi8iS0m8iE0bgTaeYTruaTVIxIHHHgoBVamuatfAKHljmpXfBsauzHN1/nDFSNSxbBAsII327HWa8GDXXHjb2pS7RXT5MSbnQo9CAkUBmFq1yFumoFV+CUhy3TGLlWP66V1ylzlvCZVFgFiKwTuqGlh6lfPflmP0UqI+8F8Wm0S4oC1XyzKEj/cktE7neAtnf0hD/XRQSUkU6nhE6eblyPEm6wrHXYtSu7oV6Z34Dg5hM2J4ulk5bkWgTsmnzBlJVwCE816oDGhlD0lFT8FDrzxTliNlnnwnQEoWfHbtrxGRNfzDIZc2vrbm4koGx/SfrWltZpCG4PIm+QEZwcNr55okdkB1y56Ib+al59aYlxNRw1jUZTAgGIxXTPQHWLLm4sU2lTJ64gdBpVmpLOREQjrIaAdxXOtofNiZpg3XrxtSblNmo1aLHCSJgMImtdiFtNyeeVnYioFH4njH5fJxjcAp+4JIBDGP6FrsjCCXfnVxkFOPDwz/4+ccUeLG48gAVwxG80ETNl/+xuACSxAJ/CqZjgRIiGz8aujAl7b5KfTGD/iEgA5jN8Yd1+4qTsEoB1Jgt0vDh1Q9hFaCOC12EAFZBewOBN81gKf+qhIcqH/wRjS1+qiZF+kKXMUjULW/UBfR53lIah/I7sKdT9wDCuoNea+QwL2aOxaF5z8wVLXqeyFOFXnLlpv0VcDPKNj1WbH0Wod9ky51Famsawycadv9SCYPgEnuBJkUZn+kRhnzrXEPp2QEnPdHeXNQyLKx4nfAXF4Lr40RJFjcsDlLoajboOwZGx1+obWSlN9KiIw/dMOCEMi6F7z8ZuZ7evMy3TgDU3OAHFdTTWaLMgE4qhFHgapVABMf97lNLtKdKywvbVhYT4TORnJEJfc/5EMel4uH/Z4aQmJDBORz+OvLsRJv1HC9myGgmywz87X8DtwqdRO2MIdlA4q5/rld9UkLqWMRbxhuvKRQ/83QIFGBRPaj6AHyjPml8HXnFGyolMBl58TiJ7yomRu7PEjZVcz4+VSi81rgDGned0iUGFTtBrQ/rblIM7yjftHefxSUtY7azT/rQQXhLNiLjQp1sIztNWbYxsXJeGwkQ92rPZjCcQgaUaRbFcbYyT1h3IDHXoOs1oGK2948kJQIduTrtr2gf+AXVSUbIK28o0C2WMF7194o9R0FvzGAm+5E8+pa1TF0WL3EsYbFH/M8bwdIsMNLVTvuiP/merEMiA78EGkJHHvC2JEYYqabNm3TFStL5o3TbTFoX6zu3fGSdpaDPZLunDLgyCzOZup/AcxeMH1N1VpYmOnGggWvsOF/NzBOQIqcYZlcRCbNj22wmFfvCL8keES5xT3jiFffMQPj5TfLeO/0W3hmkJExaLxKGbhNL8H4EYjcK0hk5+f08DxIMJBAhAQKAAAIACFAxAIAjBgAQECSlWtHgRY0aNGzluVICA4QICCwxQKNARZUqVK1mmVGCAYgGYGglQNHASgAABGmUmfNAg4QSEFylYAOAAAkYFExI2eJCwps2hLalWtXoVa1atW7l2paig/wEBoxkVFHggYMGCpwoFICiA0+vWCGYF4CwQtkFdB3H59kVZYGfCnjRt4tTJcyYAoT8zIgVQNKPTpRSjJqzrF3NmzZs5d874IEJKBGsBGzAgcqTpywoPdi5tYOAE1XZbe7bdFXDMxBgr37QcGONgABIlalwQ4XhGBMQpV1x9G3p06dMB64Q7neNbBKvvEsirEzz38OPFkwdvV8CDAqGxt9caQYJuigKmQi38O2GEsfJ9QhCqcK2KKIDIsvoAUKAguCobjj33HHTvrQKG2g0lByiYboEXQHhhgfCue1Cjj8xDzzzrBCvRRBBVxAoChJCa4EIHFrDIAAJgomACCBxAIP+tiSyIj6IXL0xoASAbmMiiCAiYSEaMJJgxoRpnUiCpFa20jQCdFthrQf4uEs454PhCgMwTNDiTAA03hPLKNt10c7uLLNhPpQb2SonNjOZkqa03/ewrqgdgqgk+A+zMqcOTBD10MAEiQki1CAQ1IECsHljghBMIMFODGjg98wQk/xyVVOgMsoi+loZEST+OUlUJgSpLndWqqBAAitC9mox1vZ8UQK6sG3cSdDgJ3lrgV1GveoCARc5chAAQNHim2WcJqJTWbLXdlttuo8uSgi0BsFWCGhWaqQEJtHwLpgnAq+mwCCaw4EOrEPhUgxMm0FSkTEfC1tuABR6Y4IJ5e6v/OQokCK2mwQyg961gx43wpMMAiEAAArXKEIQ1AbAgrEVEfgVagA0+GeWUVQaxy5oovbjhKgUA6sC5YHo4ob0EuDCC0BDcqroU7z2T6FBXPhrppJX2q+WjSKIgKtMmGrAhmw9sAAIIgIoAogcgOrWvn6I98xUQ8lwa7bTVXttgZheZJtNtCBKT7brtvhtvFYc+s4ZFXjE678AFH5zwvjju2OPCFV+c8cYzCvo8xyWfnPLKLb8c88w135zzzj3/HPTQRR+d9NJNPx311FVfnfXWXX8d9thln5322m2/Hffcdd+d9959/x344IUfnvjijT8e+eSVX5755p1/HvropZ+eE/rqrb8e++y135777r3/HvytAgIAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Activated cells of the immune system, endothelial cells, and fibroblasts are all capable of releasing cytokines and growth factors which might exert a paracrine or autocrine influence on other cells. This could in turn modulate celluar properties and induce production of the same or other factors. Thus, there is the potential for local cytokine loops to initiate and perpetuate the immunologic, vascular, and fibrotic components of scleroderma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17152=[""].join("\n");
var outline_f16_48_17152=null;
var title_f16_48_17153="IgG anaphylaxis mice";
var content_f16_48_17153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F81752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F81752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    IgG-mediated anaphylaxis in mice",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 475px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a mouse model of anaphylaxis, allergen interacts with allergen-specific IgG on the surface of macrophages, through the IgG receptor FcgammaRIII. Crosslinking of multiple IgG molecules by allergen initiates intracellular signaling and macrophage activation. In mice, macrophage-derived platelet activating factor and other inflammatory mediators trigger signs and symptoms similar to those of IgE mediated anaphylaxis in humans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17153=[""].join("\n");
var outline_f16_48_17153=null;
var title_f16_48_17154="Flail mitral leaflet apical long axis echocardiogram";
var content_f16_48_17154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/64363/aplaflmv_conv.mp4?title=Flail+mitral+leaflet+apical+long+axis+echocardiogram\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flail mitral valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical long axis view from a 2-D echocardiogram shows a flail posterior leaflet of the mitral valve. It has exaggerated motion in diastole and prolapses into the left atrium with diastole. The bright echo seen at the tip suggests that a ruptured papillary muscle as the etiology. The presence of left atrial enlargement suggests that there is significant mitral regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17154=[""].join("\n");
var outline_f16_48_17154=null;
var title_f16_48_17155="Langers lines of the abdomen";
var content_f16_48_17155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Langers lines of the abdomen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 679px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Langer's lines are lines of skin tension. Because these lines are predominantly horizontal in the abdomen, transverse incisions generate less tension in the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17155=[""].join("\n");
var outline_f16_48_17155=null;
var title_f16_48_17156="Aluminum hydroxide and magnesium carbonate: Patient drug information";
var content_f16_48_17156=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aluminum hydroxide and magnesium carbonate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16870?source=see_link\">",
"     see \"Aluminum hydroxide and magnesium carbonate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acid Gone Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Acid Gone [OTC];",
"     </li>",
"     <li>",
"      Gaviscon&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Gaviscon&reg; Liquid [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10013926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691873",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn and upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701479",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aluminum, magnesium, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take other drugs within 1 hour of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        Products with aluminum and calcium:",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705591",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        Products with magnesium:",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694590",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chew or crush tablet well. Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11047 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17156=[""].join("\n");
var outline_f16_48_17156=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132590\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013926\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013928\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013927\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013932\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013933\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013935\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013930\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013931\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013936\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013937\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16870?source=related_link\">",
"      Aluminum hydroxide and magnesium carbonate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_48_17157="Acetaminophen, chlorpheniramine, phenylephrine, and phenyltoloxamine: Patient drug information";
var content_f16_48_17157=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetaminophen, chlorpheniramine, phenylephrine, and phenyltoloxamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/45/21204?source=see_link\">",
"     see \"Acetaminophen, chlorpheniramine, phenylephrine, and phenyltoloxamine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12872684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      norel&reg; SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12990568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12990579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12990569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3478022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetaminophen, chlorpheniramine, phenylephrine, phenyltoloxamine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, glaucoma, or very high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12990574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12990570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12990576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12990573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not chew or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12990578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12990577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12990575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16787 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-CA557B663F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17157=[""].join("\n");
var outline_f16_48_17157=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12872684\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990568\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990579\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990569\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990574\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990570\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990576\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990573\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990578\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990577\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990575\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/45/21204?source=related_link\">",
"      Acetaminophen, chlorpheniramine, phenylephrine, and phenyltoloxamine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_48_17158="Conjugated equine estrogens (topical): Patient drug information";
var content_f16_48_17158=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Conjugated equine estrogens (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19399?source=see_link\">",
"     see \"Conjugated equine estrogens (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/30/14821?source=see_link\">",
"     see \"Conjugated equine estrogens (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8090835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Premarin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8090836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Premarin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700311",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Estrogens, when used in women after stopping periods (menopause), may raise the chance of uterine cancer. Progestins may lower this chance. A warning sign for cancer of the uterus is vaginal bleeding. Report any vaginal bleeding to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take estrogens if you are pregnant. If you get pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700259",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take estrogens to stop heart disease or dementia. Using estrogens may raise your chances of having a heart attack, a stroke, breast cancer, or a blood clot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or lower the signs of stopping periods (menopause).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692123",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat vaginal irritation and dryness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to estrogens (conjugated/equine) or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding disorder, blood clots, breast cancer (except in some cases where the cancer has spread), liver disease, recent heart attack, recent stroke, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697661",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There may be a higher chance of endometrial or breast cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high calcium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697245",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had high triglyceride levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697924",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breast pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There may be days when you will not take this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use cream vaginally.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11678 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-0ACB48A304-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17158=[""].join("\n");
var outline_f16_48_17158=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090835\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090836\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027332\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027334\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027333\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027338\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027339\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027341\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027336\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027337\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027342\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027343\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/51/28472?source=related_link\">",
"      Conjugated equine estrogens (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/17/41238?source=related_link\">",
"      Conjugated equine estrogens (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/29/22998?source=related_link\">",
"      Conjugated equine estrogens (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19399?source=related_link\">",
"      Conjugated equine estrogens (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/30/14821?source=related_link\">",
"      Conjugated equine estrogens (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_48_17159="Vemurafenib: Drug information";
var content_f16_48_17159=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vemurafenib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/4/31813?source=see_link\">",
"    see \"Vemurafenib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13187339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zelboraf&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13864012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zelboraf&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13182295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, BRAF Kinase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13202882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"     <b>",
"      Melanoma, metastatic or unresectable (with BRAF",
"      <sup>",
"       V600E",
"      </sup>",
"      mutation):",
"     </b>",
"     Oral: 960 mg twice daily; continue until disease progression or unacceptable toxicity.",
"     <b>",
"      Note:",
"     </b>",
"     A missed dose may be taken up to 4 hours prior to the next scheduled dose to maintain a twice daily schedule; both doses should not be taken at the same time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     <b>",
"      Melanoma, metastatic or unresectable (with BRAF",
"      <sup>",
"       V600",
"      </sup>",
"      mutation):",
"     </b>",
"     Oral: 960 mg twice daily; continue until disease progression or unacceptable toxicity.",
"     <b>",
"      Note:",
"     </b>",
"     A missed dose may be taken up to 4 hours prior to the next scheduled dose to maintain a twice daily schedule; both doses should not be taken at the same time.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13202883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13202886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment (pre-existing): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (pre-existing): Data is insufficient to determine if dosage adjustment necessary; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13202885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment (pre-existing): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (pre-existing): Data is insufficient to determine if dosage adjustment necessary; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F13202884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose reductions resulting in a dose below 480 mg twice daily are not recommended. NCI Common Terminology Criteria for Adverse Events (CTC-AE) version 4.0 used for adverse event grades.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Grade 1 or grade 2 (tolerable) toxicity:",
"     </b>",
"     No adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Grade 2 (intolerable) or grade 3 toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      First incident:",
"     </i>",
"     Interrupt treatment until toxicity returns to grade 0 or 1, then resume at 720 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Second incident:",
"     </i>",
"     Interrupt treatment until toxicity returns to grade 0 or 1, then resume at 480 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Third incident:",
"     </i>",
"     Discontinue permanently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Grade 4 toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      First incident:",
"     </i>",
"     Interrupt treatment until toxicity returns to grade 0 or 1, then resume at 480 mg twice daily",
"     <b>",
"      or",
"     </b>",
"     discontinue permanently",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Second incident:",
"     </i>",
"     Discontinue permanently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Specific toxicities:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Severe hypersensitivity or severe dermatologic toxicity:",
"     </i>",
"     Discontinue permanently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      QT",
"      <sub>",
"       c",
"      </sub>",
"      interval changes:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;500 msec (grade &ge;3): Temporarily withhold treatment, correct electrolytes and control risk factors for QT prolongation; may reinitiate with a dose reduction once QT",
"     <sub>",
"      c",
"     </sub>",
"     &lt;500 msec.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     persistently &gt;500 msec and &gt;60 msec above baseline: Discontinue permanently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      QT",
"      <sub>",
"       c",
"      </sub>",
"      interval changes:",
"     </i>",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;500 msec during treatment and &lt;60 msec change from baseline:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     First incident: Interrupt treatment until QT",
"     <sub>",
"      c",
"     </sub>",
"     &lt;500 msec, then resume at 720 mg twice daily or 480 mg twice daily if dose previously reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Second incident: Interrupt treatment until QT",
"     <sub>",
"      c",
"     </sub>",
"     &lt;500 msec, then resume at 480 mg twice daily or discontinue permanently if dose previously reduced to 480 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Third incident: Discontinue permanently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;500 msec during treatment and &gt;60 msec above baseline: Discontinue permanently.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13187340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zelboraf&trade;: 240 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13202858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F13207302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Available through specialty pharmacies.  Further information may be obtained from the manufacturer, Genentech, at 1-888-249-4918, or at file://www.zelboraf.com.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13207300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM268332.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM268332.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13202887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be administered orally in the morning and evening, ~12 hours apart. Swallow whole with a glass of water; do not crush or chew. May be taken with or without a meal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13182297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Treatment of unresectable or metastatic melanoma in patients with a BRAF",
"     <sup>",
"      V600E",
"     </sup>",
"     mutation (as detected by an FDA-approved test);",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended in patients with wild-type BRAF melanoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Canadian labeling: Treatment of unresectable or metastatic melanoma in patients with a BRAF",
"     <sup>",
"      V600",
"     </sup>",
"     mutation (as identified by a validated test)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F15800823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic melanoma in patients with a BRAF",
"     <sup>",
"      V600K",
"     </sup>",
"     mutation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13182294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vemurafenib may be confused with axitinib, regorafenib, SORAfenib, vandetanib, vismodegib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13202867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (17% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (38% to 54%), headache (23% to 27%), fever (17% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (37% to 52%; grade 3: 7% to 8%), photosensitivity (33% to 49%; grade 3: 3%), alopecia (36% to 45%), pruritus (23% to 30%), skin papilloma (21% to 30%), hyperkeratosis (24% to 28%), cutaneous squamous cell carcinoma (24%; grade 3: 22% to 24%), maculopapular rash (9% to 21%), dry skin (16% to 19%), actinic keratosis (8% to 17%), seborrheic keratosis (10% to 14%), sunburn (10% to 14%), erythema (8% to 14%), papular rash (5% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (35% to 37%; grade 3: 2%), diarrhea (28% to 29%; grade 3: &lt;1%), vomiting (18% to 26%; grade 3: 1% to 2%), appetite decreased (18% to 21%), constipation (12% to 16%), taste alteration (11% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: GGT increased (5% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (53% to 67%), myalgia (13% to 24%), limb pain (9% to 18%), back pain (8% to 11%), musculoskeletal pain (8% to 11%), weakness (2% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (8% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &le;10% and/or case reports:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Atrial fibrillation, hypotension, QT prolongation, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness, nerve paralysis (VII)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Basal cell carcinoma, erythema nodosum, folliculitis, keratosis pilaris, melanoma (new primary), palmar-plantar erythrodysesthesia, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increase, AST increased, bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthritis, peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision, iritis, photophobia, retinal vein occlusion, uveitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13202863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to vemurafenib or any component of the formulation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13202864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cutaneous squamous cell carcinoma (cuSCC): Squamous cell carcinomas, both skin and keratoacanthomas, have been reported. Generally occurs early in the treatment course (median onset: 7-8 weeks) and is managed with excision (while continuing vemurafenib treatment). Approximately one-third of patients experienced &gt;1 occurrence and the median time between occurrences was 6 weeks. Potential risk factors for cuSCC include age &ge;65 years, history of skin cancer or chronic sun exposure. Monitor for skin lesions (with dermatology evaluation) at baseline and every 2 months during treatment; consider continued monitoring for 6 months after treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dermatologic toxicity: Dermatologic reactions have been observed, including case reports of Stevens-Johnson syndrome and toxic epidermal necrolysis. Discontinue (permanently) for severe dermatologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: Increases in liver function tests have been reported. Monitor transaminases, alkaline phosphatase, and bilirubin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity: Severe hypersensitivity, including anaphylaxis, rash (generalized), erythema, or hypotension have been reported with use and following reinitiation of treatment. Discontinue (permanently) with severe hypersensitivity reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Melanoma: New primary melanoma lesions were observed during treatment and were managed with excision while continuing treatment (at the same dose). Continue to monitor for skin lesions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular toxicity: Uveitis cases have been reported; monitor for signs and symptoms; may be managed with corticosteroid and mydriatic eye drops. Cases of blurred vision, iritis, photophobia, and a single case of retinal vein occlusion have been reported from clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Photosensitivity: Photosensitivity ranging from mild to severe has been reported. Advise patients to avoid sun exposure and wear protective clothing and use effective UVA/UVB sunscreen and lip balm (SPF &ge;30) when outdoors. Dosage modifications are recommended for intolerable photosensitivity consisting of erythema &ge;10% to 30% of body surface area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; QT prolongation: QT prolongation (dose-dependent) has been observed; may lead to increased risk for ventricular arrhythmia, including torsade de pointes. Monitor electrolytes (calcium, magnesium and potassium) at baseline and with dosage adjustments. Monitor ECG at baseline, 15 days after initiation, then monthly for 3 months, then every 3 months thereafter (more frequently if clinically appropriate); also monitor with dosage adjustments. Do not initiate treatment if baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;500 msec. During treatment, if QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;500 msec, temporarily interrupt treatment; correct electrolytes and control other risk factors for QT prolongation. May reinitiate with a dose reduction once QT",
"     <sub>",
"      c",
"     </sub>",
"     falls to &lt;500 msec. Discontinue (permanently), if after correction of risk factors, both the QT",
"     <sub>",
"      c",
"     </sub>",
"     continues to increase &gt;500 msec and there is &gt;60 msec change above baseline. Use is not recommended in patients with electrolyte abnormalities which are not correctable, long QT syndrome, or taking concomitant medication known to prolong the QT interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: May be at increased risk for adverse effects; in clinical trials, there was an increased incidence of cuSCC and keratoacanthoma, atrial fibrillation, peripheral edema, and nausea/decreased appetite in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; BRAF genomics: Only patients with a BRAF",
"     <sup>",
"      V600",
"     </sup>",
"     mutation-positive melanoma (including BRAF",
"     <sup>",
"      V600E",
"     </sup>",
"     ) will benefit from treatment; mutation must be detected and confirmed by an FDA-approved test prior to treatment. The cobas&reg; 4800 BRAF V600 Mutation Test was used in clinical trials and is FDA-approved to detect BRAF",
"     <sup>",
"      V600E",
"     </sup>",
"     mutation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (moderate), CYP2D6 (weak), P-glycoprotein;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13225913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13202859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13202860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were not demonstrated in animal reproduction studies. Based on the mechanism of action, vemurafenib may cause fetal harm if administered during pregnancy or in patients who become pregnant during treatment. Women of childbearing potential and men of reproductive potential should use adequate contraception methods during and for at least 2 months after treatment (Canadian labeling recommends during and for at least 6 months after treatment).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13202861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13202862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue vemurafenib or to discontinue breast-feeding during treatment should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13202899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zelboraf Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (120): $6510.48",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13202900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver transaminases, alkaline phosphatase and bilirubin at baseline and monthly during treatment (or as clinically appropriate). Electrolytes (calcium, magnesium and potassium) at baseline and after dosage modification. ECG at baseline, 15 days after initiation, then monthly for 3 months, then every 3 months thereafter (more frequently if clinically appropriate) and with dosage adjustments. Dermatology evaluation (for new skin lesions) at baseline and every 2 months during treatment; also consider continued monitoring for 6 months after completion of treatment. Signs/symptoms of uveitis.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13733209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Zelboraf (CH, CZ, DE, DK, EE, FR, GB, IL, NO, NZ, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13202872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BRAF kinase inhibitor (potent) which inhibits tumor growth in melanomas by inhibiting kinase activity of certain mutated forms of BRAF, including BRAF with V600E mutation, thereby blocking cellular proliferation in melanoma cells with the mutation. Does not have activity against cells with wild-type BRAF. BRAF",
"     <sup>",
"      V600E",
"     </sup>",
"     activating mutations present in ~50% of melanomas; V600E mutation involves the substitution of glutamic acid for valine at amino acid 600. The cobas&reg; 4800 BRAF V600 mutation test is approved to detect BRAF",
"     <sup>",
"      V600E",
"     </sup>",
"     mutation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13202874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~106 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99%, to albumin and &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: 57 hours (range: 30-120 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (~94%); urine (~1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bloom KJ, Anderson SM, Schilling RC, et al, &ldquo;Molecular Testing for BRAF V600 Mutations in the BRIM-2 Trial of the BRAF Inhibitor Vemurafenib in Metastatic Melanoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(15s):10523 [abstract 10523 from ASCO 2011 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bollag G, Hirth P, Tsai J, et al, &ldquo;Clinical Efficacy of a RAF Inhibitor Needs Broad Target Blockade in BRAF-Mutant Melanoma,&rdquo;",
"      <i>",
"       Nature",
"      </i>",
"      , 2010, 467(7315):596-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17159/abstract-text/20823850/pubmed\" id=\"20823850\" target=\"_blank\">",
"        20823850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman PB, Hauschild A, Robert C, et al, &ldquo;Improved Survival With Vemurafenib in Melanoma With BRAF V600E Mutation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(26):2507-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17159/abstract-text/21639808/pubmed\" id=\"21639808\" target=\"_blank\">",
"        21639808",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flaherty KT, Puzanov I, Kim KB, et al, &ldquo;Inhibition of Mutated, Activated BRAF in Metastatic Melanoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(9):809-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17159/abstract-text/20818844/pubmed\" id=\"20818844\" target=\"_blank\">",
"        20818844",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McArthur GA, Ribas A, Chapman PB, et al, &ldquo;Molecular Analyses From a Phase I Trial of Vemurafenib to Study Mechanism of Action (MOA) and Resistance in Repeated Biopsies From BRAF Mutation&ndash;Positive Metastatic Melanoma Patients (pts),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(15s):8502 [abstract 8502 from ASCO 2011 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Available at",
"      <a href=\"file://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40_conversion\" target=\"_blank\">",
"       file://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40_conversion",
"      </a>",
"      . Last accessed October 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ribas A, Kim KB, Schuchter LM, et al, &ldquo;BRIM-2: An Open-Label, Multicenter Phase II Study of Vemurafenib in Previously Treated Patients With BRAF V600E Mutation-Positive Metastatic Melanoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(15s):8509 [abstract 8509 from ASCO 2011 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sosman JA, Kim KB, Schuchter L, et al, &ldquo;Survival in BRAF V600-Mutant Advanced Melanoma Treated With Vemurafenib,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(8):707-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17159/abstract-text/22356324/pubmed\" id=\"22356324\" target=\"_blank\">",
"        22356324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Su F, Viros A, Milagre C, et al, &ldquo;RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated With BRAF Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(3):207-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17159/abstract-text/22256804/pubmed\" id=\"22256804\" target=\"_blank\">",
"        22256804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Su F, Yang H, Higgins B, et al, &ldquo;Molecular Mechanisms Underlying Disease Relapse on Treatment With Selective BRAF Inhibitor Vemurafenib (PLX4032),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(15s):8517 [abstract 8517 from ASCO 2011 Annual Meeting].",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16798 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-A044F949FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17159=[""].join("\n");
var outline_f16_48_17159=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13187339\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13864012\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182295\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202882\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202883\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202886\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202885\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202884\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13187340\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202858\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13207302\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13207300\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202887\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182297\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15800823\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182294\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202867\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202863\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202864\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300213\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225913\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202859\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202860\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202861\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202862\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202899\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322912\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202900\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733209\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202872\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13202874\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16798|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/4/31813?source=related_link\">",
"      Vemurafenib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_48_17160="Insulin lispro: Drug information";
var content_f16_48_17160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin lispro: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/49/42772?source=see_link\">",
"    see \"Insulin lispro: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/40/14982?source=see_link\">",
"    see \"Insulin lispro: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2127784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumaLOG&reg;;",
"     </li>",
"     <li>",
"      HumaLOG&reg; KwikPen&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2127785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humalog&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2127789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Insulin, Rapid-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2127828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Insulin lispro is a rapid-acting insulin analog which is normally administered SubQ as a premeal component of the insulin regimen or as a continuous SubQ infusion and should be used with intermediate- or long-acting insulin. When compared to insulin regular, insulin lispro has a more rapid onset and shorter duration of activity. In carefully controlled clinical settings with close medical supervision and monitoring of blood glucose and potassium, insulin lispro may also be administered I.V. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are the standard of diabetes care. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Initial total insulin dose:",
"     </b>",
"     0.2-0.6 units/kg/day in divided doses. Conservative initial doses of 0.2-0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. A rapid-acting insulin may be the only insulin formulation used initially.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     0.5-1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (&ldquo;conventional therapy&rdquo;):",
"     </b>",
"     Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate- or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting (eg, insulin aspart) or short-acting form of insulin. Some patients may benefit from the use of CSII which delivers rapid-acting insulin (insulin aspart) as a continuous infusion throughout the day and as boluses at mealtimes via an external pump device.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (&ldquo;intensive therapy&rdquo;):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of short- or rapid-acting insulin (eg, insulin aspart) formulations 3 or more times daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized. Also see Additional Information or Pharmacotherapy Pearls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Continuous SubQ insulin infusion (insulin pump):",
"     </b>",
"     A combination of a \"basal\" continuous insulin infusion rate with preprogrammed, premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of the longer acting insulin (eg, NPH); divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 2:",
"     </b>",
"     SubQ: Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate): Initial dosage of 0.2 units/kg/day or 10 units/day of an intermediate-acting (eg, NPH) or long-acting insulin administered at bedtime has been recommended. As an alternative, regular insulin or rapid-acting insulin formulations administered before meals have also been used. Dosage must be carefully adjusted.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2127827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/40/14982?source=see_link\">",
"      see \"Insulin lispro: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     Children &ge;3 years and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diabetic ketoacidosis (DKA), mild-to-moderate (unlabeled use):",
"     </b>",
"     Children and Adolescents: Treatment should continue until reversal of acid-base derangement/ketonemia. Serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. Also refer to institution-specific protocols where appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     SubQ (",
"     <b>",
"      Note:",
"     </b>",
"     Use of I.V. regular insulin is preferred; only use the SubQ route if I.V. infusion access is unavailable): 0.3 units/kg  followed in 1 hour by 0.1 units/kg given every hour or 0.15-0.2 units/kg every 2 hours; continue until acidosis clears, then decrease to 0.05 units/kg given every hour until maintenance SubQ replacement dosing can be initiated (Kitabchi, 2004; Wolfsdorf, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2308015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2127829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Insulin requirements are reduced due to changes in insulin clearance or metabolism. No dosage adjustment provided in manufacturer&rsquo;s labeling; however, the following adjustments have been recommended (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer at 75% of recommended dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer at 50% of recommended dose and monitor glucose closely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: Because of a large molecular weight (6000 daltons), insulin is not significantly removed by either peritoneal or hemodialysis; supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Continuous renal replacement therapy: Administer at 75% of recommended dose",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8103637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumaLOG&reg;: 100 units/mL (3 mL) [cartridge]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumaLOG&reg;: 100 units/mL (3 mL, 10 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumaLOG&reg; KwikPen&trade;: 100 units/mL (3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2127787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2127831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. Insulin lispro should be administered within 15 minutes before or immediately after a meal. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites. When mixing insulin lispro with other preparations of insulin (eg, insulin NPH), insulin lispro should be drawn into syringe first. Do not dilute or mix other insulin formulations with insulin lispro contained in a cartridge or prefilled pen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CSII administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. Patients should be trained in the proper use of their external insulin pump and in intensive insulin therapy. Infusion sets and infusion set insertion sites should be changed every 3 days; rotate infusion sites. Insulin in reservoir should be changed every 7 days. Do not dilute or mix other insulin formulations with insulin lispro contained in an external insulin pump.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. administration (unlabeled use): Do not use if solution is viscous or cloudy; use only if clear and colorless. May be administered I.V. with close monitoring of blood glucose and serum potassium; appropriate medical supervision is required.",
"     <b>",
"      Do not administer insulin mixtures intravenously.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. infusions: To minimize adsorption to I.V. solution bag:",
"     <b>",
"      Note:",
"     </b>",
"     Refer to institution-specific protocols where appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      If new tubing is",
"     </i>",
"     <b>",
"      <i>",
"       not",
"      </i>",
"     </b>",
"     <i>",
"      needed:",
"     </i>",
"     Wait a minimum of 30 minutes between the preparation of the solution and the initiation of the infusion. Wait a minimum of 30 minutes between the preparation of the solution and the initiation of the infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      If new tubing is needed:",
"     </i>",
"     After receiving the insulin drip solution, the administration set should be attached to the I.V. container and the entire line should be flushed with a priming infusion of 20-50 mL of the insulin solution (Goldberg, 2006; Hirsch, 2006). Wait 30 minutes, and then flush the line again with the insulin solution prior to initiating the infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Because of adsorption, the actual amount of insulin being administered via I.V. infusion could be substantially less than the apparent amount. Therefore, adjustment of the I.V. infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SubQ dosing regimen (Moghissi, 2009); however, the transition to SubQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SubQ insulin should be given 1-4 hours prior to the discontinuation of I.V. insulin to prevent hyperglycemia (Moghissi, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2127815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W and NS.",
"     <b>",
"      Note:",
"     </b>",
"     A universal sterile diluent, Sterile Diluent for Humalog&reg;, Humulin&reg; N, Humulin&reg; R, Humulin&reg; 70/30, and Humulin&reg; R U-500, is available from the manufacturer for SubQ administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Insulin NPH.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Insulin aspart, insulin detemir, insulin glargine, insulin glulisine, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2127792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8103633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gestational diabetes mellitus (GDM); mild-to-moderate diabetic ketoacidosis (DKA); mild-to-moderate hyperosmolar hyperglycemic state (HHS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2127781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       HumaLOG&reg; may be confused with HumaLOG&reg; Mix 50/50, Humira&reg;, HumuLIN&reg; N, HumuLIN&reg; R, NovoLOG&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2127804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2127798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to insulin lispro or any component of the formulation; during episodes of hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2127799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage or even death. Insulin requirements may be altered during illness, emotional disturbances or other stressors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Insulin (especially I.V. insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium frequently with I.V. use and supplement potassium when necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of sliding scale insulin in this population due to increased risk of hypoglycemia without benefits in management of hyperglycemia regardless of care setting (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin [eg, insulin lispro]) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Due to the short duration of action of insulin lispro, a longer acting insulin or CSII via an external insulin pump is needed to maintain adequate glucose control in patients with type 1 diabetes mellitus. In both type 1 and type 2 diabetes, preprandial administration of insulin lispro should be immediately followed by a meal within 15 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CSII administration: May be administered via CSII; do not dilute or mix with other insulin formulations. Rule out external pump failure if unexplained hyperglycemia or ketosis occurs; temporary SubQ insulin administration may be required until the problem is identified and corrected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Insulin lispro may be administered I.V. in selected clinical situations to control hyperglycemia; close monitoring of blood glucose and serum potassium as well as medical supervision is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2127810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2127809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2127812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Use caution with ethanol; may increase risk of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Use caution with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle; may increase risk of hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2127793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2127794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Insulin lispro has not been shown to cross the placenta at standard clinical doses. Although congenital anomalies have been noted in case reports, when compared to regular insulin, insulin lispro has not been found to increase the risk of adverse events to the fetus in larger studies. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy. The use of insulin lispro has been shown to be as effective as regular insulin to treat diabetes in pregnancy and may have advantages over regular insulin during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2127796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/compatible",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2127797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if insulin lispro distributes into breast milk. Endogenous insulin can be found in breast milk. Plasma glucose concentrations in the mother affect glucose concentrations in breast milk. The gastrointestinal tract destroys insulin when administered orally; therefore, insulin is not expected to be absorbed intact by the breast-feeding infant. All types of insulin are safe for use while breast-feeding. Due to increased calorie expenditure, women with diabetes may require less insulin while nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2127830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (HumaLOG KwikPen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (3 mL): $65.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (HumaLOG Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (3 mL): $62.62",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2127833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diabetes mellitus: Plasma glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. administration (unlabeled use): Close monitoring of blood glucose and serum potassium",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2127818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic, serum insulin (fasting): 5-20 &mu;IU/mL (SI: 35-145 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elderly: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes mellitus (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak postprandial capillary plasma glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Humalog (AT, AU, BB, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CZ, DE, DK, ET, FI, FR, GB, GH, GM, GN, GR, GY, HN, ID, IE, IN, IT, JM, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, NL, NO, PK, PT, PY, RU, SC, SD, SE, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Humalog Lispro (CR, GT, HN, IL, KP, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Humalog Mix NPL (AT, BE, BG, CH, CZ, DE, DK, FI, FR, GB, GR, HN, IE, IT, NL, NO, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Insulin Humalog (PL);",
"     </li>",
"     <li>",
"      Insuline Lispro Humalog (FR);",
"     </li>",
"     <li>",
"      Liprolog (AT, BE, BG, CH, CZ, DE, DK, FI, FR, GB, GR, HN, IE, IT, NL, NO, PT, RU, SE, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2127816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin lispro is a rapid-acting insulin analog.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2127819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Rate of absorption, onset, and duration of activity may be affected by site of injection, exercise, presence of lipodystrophy, local blood supply, and/or temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 0.25-0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect: 0.5-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &le;5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.26-0.36 L/kg",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Bioavailability: 55% to 77%",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;\">",
"     I.V.: ~0.5-1 hour (dose-dependent)",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;\">",
"     SubQ: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 0.5-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists Committee on Practice Bulletins, &ldquo;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 30, September 2001 (Replaces Technical Bulletin Number 200, December 1994). Gestational Diabetes,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2001, 98(3):525-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/11547793/pubmed\" id=\"11547793\" target=\"_blank\">",
"        11547793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Gestational Diabetes Mellitus,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(Suppl 1):88-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/14693936/pubmed\" id=\"14693936\" target=\"_blank\">",
"        14693936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, \"Standards of Medical Care in Diabetes--2012,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel,  \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 2008, 32(Suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies M, Storms F, Shutler S,  et al,  \"Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of Two Treatment Algorithms Using Insulin Glargine,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(6):1282-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/15920040/pubmed\" id=\"15920040\" target=\"_blank\">",
"        15920040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerstein HC, Yale JF, Harris SB, et al,  \"A Randomized Trial of Adding Insulin Glargine Vs. Avoidance of Insulin in People With Type 2 Diabetes on Either No Oral Glucose-Lowering Agents or Submaximal Doses of Metformin and/or Sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study,\"",
"      <i>",
"       Diabet Med,",
"      </i>",
"      2006, (7):736-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/16842477/pubmed\" id=\"16842477\" target=\"_blank\">",
"        16842477",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldberg PA, Kedves A, Walter K, et al, \"'Waste Not, Want Not': Determining the Optimal Priming Volume for Intravenous Insulin Infusions,\"",
"      <i>",
"       Diabetes Technol Ther",
"      </i>",
"      , 2006, 8(5):598-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/17037974/pubmed\" id=\"17037974\" target=\"_blank\">",
"        17037974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heller S, McCance DR, Moghissi E, et al,  \"Diversity in Diabetes: The Role of Insulin Aspart,\"",
"      <i>",
"       Diabetes Metab Res Rev,",
"      </i>",
"      2012, 28(1):50-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/21695769/pubmed\" id=\"21695769\" target=\"_blank\">",
"        21695769",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kitabchi AE, Umpierrez GE, Miles JM, et al, \"Hyperglycemic Crises in Adult Patients With Diabetes,\"",
"      <i>",
"       Diabetes Care,",
"      </i>",
"      2009, 32(7):1335-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/19564476/pubmed\" id=\"19564476\" target=\"_blank\">",
"        19564476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kitabchi AE, Umpierrez GE, Murphy MB, et al, \" Hyperglycemic Crises in Diabetes,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(Suppl 1):S94-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/14693938/pubmed\" id=\"14693938\" target=\"_blank\">",
"        14693938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meneghini L, Koenen C, Rojas P, et al, &ldquo;Efficacy and Safety of Insulin Detemir in a Large Cohort of Patients With Type 2 Diabetes Using a Simplified Self-Adjusted Dosing Guideline -- Results of the Predictive 303 Study,&rdquo; Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-25, 2007; Chicago, Ill.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moghissi ES, Korytkowski MT, DiNardo M, et al, \"American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control,\"",
"      <i>",
"       Endocr Pract,",
"      </i>",
"      2009,15(4):353-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/19454396/pubmed\" id=\"19454396\" target=\"_blank\">",
"        19454396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse JB, Davidson MB, et al, \"Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al, \"Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riddle MC, Rosenstock J, Gerich J, et al, \"The Treat-To-Target Trial: Randomized Addition of Glargine or Human NPH Insulin to Oral Therapy of Type  2 Diabetic Patients,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2003, 26(11):3080-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/14578243/pubmed\" id=\"14578243\" target=\"_blank\">",
"        14578243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein J, Klingensmith G, Copeland K, et al,\" Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(1):186-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/15616254/pubmed\" id=\"15616254\" target=\"_blank\">",
"        15616254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Umpierrez GE, Cuervo R, Karabell A, et al, \"Treatment of Diabetic Ketoacidosis With Subcutaneous Insulin Aspart,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(8):1873-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/15277410/pubmed\" id=\"15277410\" target=\"_blank\">",
"        15277410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Umpierrez GE, Jones S, Smiley D, et al, \"Insulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis: A Randomized Controlled Trial,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(7):1164-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/19366972/pubmed\" id=\"19366972\" target=\"_blank\">",
"        19366972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolfsdorf J, Craig ME, Daneman D, et al, &ldquo;Diabetic Ketoacidosis,&rdquo;",
"      <i>",
"       Pediatr Diabetes",
"      </i>",
"      , 2007, 8(1):28-43. Available at file://www.ispad.org/FileCenter/10-Wolfsdorf_Ped_Diab_2007,8.28-43.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/48/17160/abstract-text/17341289/pubmed\" id=\"17341289\" target=\"_blank\">",
"        17341289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9025 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-850F4342A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17160=[""].join("\n");
var outline_f16_48_17160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127784\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127785\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127789\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127828\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127827\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2308015\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127829\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103637\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104242\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127787\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127831\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127815\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127792\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103633\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127781\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127804\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127798\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127799\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127810\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127809\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127812\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127793\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127794\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127796\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127797\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127830\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422168\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127833\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127818\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869462\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127816\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127819\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9025\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9025|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/49/42772?source=related_link\">",
"      Insulin lispro: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/40/14982?source=related_link\">",
"      Insulin lispro: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_48_17161="Medication overuse headache: Treatment and prognosis";
var content_f16_48_17161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medication overuse headache: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/48/17161/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/48/17161/contributors\">",
"     Ivan Garza, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/48/17161/contributors\">",
"     Todd J Schwedt, MD, MSCI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/48/17161/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/48/17161/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/48/17161/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/48/17161/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/48/17161/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic daily headache is a descriptive term that encompasses several different specific headache diagnoses. Chronic daily headache types of long duration (ie, four hours or more) include chronic migraine, chronic tension-type headache, medication overuse headache, hemicrania continua, and new daily persistent headache.",
"   </p>",
"   <p>",
"    Medication overuse headache (MOH) is a common problem in clinical practice that needs to be properly managed in order to increase the likelihood of successful chronic daily headache treatment.",
"   </p>",
"   <p>",
"    This topic will review the treatment and prognosis of MOH. Other clinical aspects of MOH are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=see_link\">",
"     \"Medication overuse headache: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The remaining subtypes of chronic daily headache are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=see_link\">",
"     \"Overview of chronic daily headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Withdrawal of the overused medication as soon as possible is the treatment of choice for medication overuse headache (MOH) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/1\">",
"     1",
"    </a>",
"    ]. It is also important to educate patients about the detrimental effects of analgesic overuse. Bridge (transitional) therapy may be useful during drug withdrawal to provide symptomatic relief. For most patients, a preventive (prophylactic) medication aimed at the suspected background primary headache disorder (eg, migraine) should be initiated either during or immediately following withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2\">",
"     2",
"    </a>",
"    ]. Screening and intervening for comorbid psychiatric and substance use disorders is also recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the overused medications have been withdrawn, an ongoing headache treatment regimen is needed for acute and preventive therapy, since patients frequently return to a pattern of intermittent headaches. Close follow-up after withdrawal of the overused analgesics is imperative to evaluate progress and prevent relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATIENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians must educate patients about the detrimental effects of analgesic overuse [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients need to understand that analgesics have the potential to cause MOH, and that analgesic overuse can negate the effectiveness of headache preventive measures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited, adequate patient education and support play a major role in withdrawal therapy of MOH. A prospective, unblinded trial of 120 patients with migraine plus MOH randomly assigned patients to either strong advice to withdraw the overused medication, or to a structured inpatient or outpatient detoxification program [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients in all three groups were instructed to stop the overused medication, and all were permitted to use NSAIDs or triptans not more than two days a week for symptomatic relief. Approximately 75 percent of patients in all groups were successfully treated for analgesic withdrawal. The trial excluded patients who overused agents containing opioids, benzodiazepines and barbiturates, and those with coexisting medical or psychiatric illness, and the results may not be generalizable to all patients with MOH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WITHDRAWAL OF THE OVERUSED MEDICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of short-term benefit following medication withdrawal for patients with MOH is suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 17 studies and 1101 patients with MOH defined treatment success as either no headache at all or a reduction in headache days of &gt;50 percent following withdrawal therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/5\">",
"       5",
"      </a>",
"      ]. The mean success rate within one to six months after withdrawal was 72 percent.",
"     </li>",
"     <li>",
"      An uncontrolled prospective study evaluated 175 patients with probable MOH, all of whom complied with abrupt withdrawal of acute headache medication and a two month medication-free period [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/6\">",
"       6",
"      </a>",
"      ]. After the medication-free period, prophylactic treatment was started and follow-up continued for a mean time of 228 days. Approximately one-half of patients had a significant reduction in headache frequency with discontinuation of the offending drug. In the remaining 50 percent of patients, who showed no improvement at two months after drug discontinuation, there was a significant 26 percent decrease in headache frequency after the end of the medication-free period until the end of the study. The authors concluded that acute medication withdrawal resulted in a responsive state amenable to prophylactic intervention.",
"     </li>",
"     <li>",
"      Results from an early observational study suggest that daily concomitant use of analgesic medications may reduce the effect of prophylactic medications, while discontinuing daily analgesic medications enhances the beneficial effect of prophylactic medications [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/7\">",
"       7",
"      </a>",
"      ]. The study evaluated 200 patients with daily or near daily headache in the setting of analgesic (symptomatic) medication overuse. Patients on analgesic medications only at baseline were divided into three treatment groups of 28 patients each. At three months of follow-up, the treatments and corresponding improvements in the headache indices were as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Analgesics continued: 21 percent",
"     </li>",
"     <li>",
"      Analgesics stopped: 58 percent",
"     </li>",
"     <li>",
"      Analgesics stopped, prophylaxis started: 85 percent",
"      <br/>",
"      <br/>",
"      Patients who were already on concomitant prophylactic headache medications at study entry were divided into two treatment groups of 58 patients each [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/7\">",
"       7",
"      </a>",
"      ]. At three months of follow-up, the treatments and corresponding improvements in the headache indices were as follows:",
"     </li>",
"     <li>",
"      Analgesics stopped, prophylaxis unchanged: 72 percent",
"     </li>",
"     <li>",
"      Analgesics stopped, prophylaxis changed: 86 percent",
"      <br/>",
"      <br/>",
"      The strength of this study is limited by its unblinded, open label methodology and by small patient numbers in the subgroups [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/7\">",
"       7",
"      </a>",
"      ]. Nevertheless, the findings support the concept that analgesic overuse is deleterious for patients with frequent headache.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Outpatient and inpatient strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Withdrawal of overused acute medications can be accomplished on an outpatient or inpatient basis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2\">",
"     2",
"    </a>",
"    ]. Most patients can be managed as outpatients. Outpatient withdrawal is particularly appropriate for patients who are highly motivated and do not take barbiturates or tranquilizers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant complications may occur as a consequence of drug dependency when withdrawing from opioids, benzodiazepines and barbiturates, and the choice between outpatient and inpatient withdrawal of these agents remains an area of debate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/9\">",
"     9",
"    </a>",
"    ]. Some experts favor inpatient withdrawal with close observation and medical monitoring in the first several days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/10\">",
"     10",
"    </a>",
"    ]. However, it is often reasonable to try outpatient treatment first unless serious withdrawal problems develop or are considered likely.",
"   </p>",
"   <p>",
"    In addition to the number and type of overused substances, variables influencing the choice between outpatient and inpatient management include family support structure, patient motivation, medical stability, presence of coexisting medical illness, psychological and psychiatric comorbidities, and need for patient monitoring during administration of medical therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/3,10\">",
"     3,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The suggested outpatient approach for withdrawal of overused medications other than barbiturates, opioids, or benzodiazepines is straightforward [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Withdraw the overused medication abruptly",
"     </li>",
"     <li>",
"      Use bridge therapy with a long-acting NSAID or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"     </li>",
"     <li>",
"      Start a preventive medication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With overuse of barbiturates, opioids, or benzodiazepines, the pace of withdrawal depends on the amount and frequency of usage. Abrupt outpatient withdrawal is routinely done in clinical practice if intake of the offending agent is not very high. However, we suggest a gradual taper when these agents (particularly barbiturates or benzodiazepines) are being used frequently or at high doses. The taper can usually be accomplished in two to four weeks.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients withdrawing from butalbital, we recommend a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      taper for seizure prophylaxis, particularly when butalbital is stopped abruptly or when high doses are being used. Our suggested regimen is phenobarbital 30 mg twice daily for two weeks, followed by 15 mg twice daily for two weeks.",
"     </li>",
"     <li>",
"      When there is concern for opioid withdrawal symptoms, treatment with a once-weekly transdermal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      patch (0.1 to 0.2",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours) for one to two weeks may help.",
"     </li>",
"     <li>",
"      Bridge therapy with a long-acting NSAID daily and initiation of a preventive medication is suggested to accompany withdrawal of these agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An inpatient protocol originally suggested for transformed migraine with medication overuse is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Withdraw the overused medication abruptly. However, opioids may need to be tapered rather than abruptly stopped if high doses are being overused.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When there is concern for opioid withdrawal symptoms, treat with a once-weekly transdermal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      patch (0.1 to 0.2",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours) for one to two weeks; alternatively, clonidine can be given as needed for withdrawal symptoms (0.1 to 0.2 mg three times daily, titrated up or down based on symptoms).",
"     </li>",
"     <li>",
"      Treat with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      30 mg twice daily for two weeks followed by 15 mg twice daily for two weeks if abruptly withdrawing butalbital.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use intravenous bridge therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"       dihydroergotamine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      sodium, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Start a preventive medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Withdrawal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the period of analgesic withdrawal, the headaches are likely to exacerbate before subsequently improving [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition to increased headache, withdrawal symptoms can include nausea, vomiting, restlessness, anxiety, nervousness, and disturbed sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Withdrawal symptoms typically last 2 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/5\">",
"     5",
"    </a>",
"    ], but occasionally can persist for as long as two to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration and severity of withdrawal headache depends on the type of overused analgesic. In one prospective study of 95 patients, the mean duration of withdrawal headache was 4.1 days for triptans, 6.7 days for ergots, and 9.5 days for analgesics (most of which were combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    , caffeine, or barbiturates) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/11\">",
"     11",
"    </a>",
"    ]. Overall, withdrawal from triptan-induced MOH was less severe than withdrawal from other analgesics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BRIDGE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bridge therapy, also known as transitional therapy, is used to provide symptomatic relief for patients with MOH during withdrawal of the offending medication. Bridge therapy strategies that appear to have some merit include the short-term use of certain oral (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    , glucocorticoids) and intravenous (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , valproic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) medications.",
"   </p>",
"   <p>",
"    The data supporting these strategies are largely from case series, retrospective chart reviews, prospective uncontrolled studies, and expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2\">",
"     2",
"    </a>",
"    ]. At the present time, no high-quality comparative studies exist regarding the different options for analgesic withdrawal. Given the available data, reviewed below, we suggest use of bridge therapy during outpatient withdrawal of the offending medication using either long-acting NSAIDs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , or subcutaneous DHE. Antiemetics are also frequently needed in clinical practice.",
"   </p>",
"   <p>",
"    For inpatient withdrawal, we suggest intravenous bridge therapy using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    sodium, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Naproxen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from two small studies suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    is useful as bridge therapy during withdrawal of overused analgesic medications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 22 patients, the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      withdrawal symptoms was studied during inpatient treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/12\">",
"       12",
"      </a>",
"      ]. Ten patients were given symptomatic medication (antiemetics, analgesics, and hydration) as needed, while 12 patients were treated with naproxen (500 mg twice daily) starting one day before the ergotamine withdrawal was initiated and continuing until the withdrawal was complete. By the eighth day after withdrawal, those on naproxen had significantly less pain, nausea, vomiting, and restlessness.",
"     </li>",
"     <li>",
"      A second study with 30 subjects treated MOH on an outpatient basis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/13\">",
"       13",
"      </a>",
"      ]. The regimen involved patient education, abrupt withdrawal of offending medications (analgesics",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      caffeine), use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      for symptomatic relief, and prophylactic medication. Improvement with a &gt;75 percent reduction in headache frequency and intensity was observed in 20 patients (67 percent), all of whom remained off analgesics entirely. Improvement with a 50 to 75 percent reduction in headache frequency and intensity was reported in nine patients (30 percent). The results, however, were obtained at 2.5 months of treatment. It is therefore impossible to attribute the benefit to naproxen alone since it is likely that prophylaxis contributed to improved outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One suggested bridge therapy regimen is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    550 mg twice daily for two to four weeks while the overused acute medication is withdrawn [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2\">",
"     2",
"    </a>",
"    ]. An alternative is naproxen 550 mg twice daily for one week, and then naproxen once daily for one week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tizanidine plus nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bridge therapy using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    combined with a nonsteroidal antiinflammatory drug (NSAID) may be effective for MOH.",
"   </p>",
"   <p>",
"    The evidence comes from one retrospective study of a subset of 55 outpatients with transformed migraine and medication overuse headache who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    (started at 2 mg at bedtime) plus a long-acting NSAID (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    sustained release, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients were instructed to stop frequent use of the suspected offending analgesics and to self-administer triptans or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    for severe headache; triptans were not permitted if they were the offending drugs. Tizanidine was titrated up by 2 mg every three to five days until a therapeutic effect or sedation occurred. The mean daily tizanidine dose was 3.6 mg (range 2 to 16 mg). At six weeks, the number of responders (ie, those with no or trivial analgesic use) was 36 patients (65 percent). The treatment protocol was well tolerated. However, the findings are limited by the retrospective design and the concurrent use of triptans and dihydroergotamine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of oral glucocorticoids for MOH bridge therapy is uncertain, as illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized controlled trial of 100 adults with probable medication overuse headache concluded that oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      has no effect on withdrawal headache [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/15\">",
"       15",
"      </a>",
"      ]. In the cohort, primary headache types were migraine (n = 65), tension-type headache (n = 13), and both migraine and tension-type headache (n = 22). Patients were randomly assigned to receive six days of treatment with either prednisolone (60 mg on days one and two, 40 mg on days three and four, and 20 mg on days five and six) or placebo tablets. During the first three days, patients were admitted to the hospital to begin withdrawal. On intention-to-treat analysis, there was no difference between prednisolone and placebo on any of the primary or secondary outcome measures. However, the absence of benefit may have been due to an insufficient dose and duration of therapy. In the clinical experience of some experts,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      50 mg daily for 10 days is often effective.",
"     </li>",
"     <li>",
"      In another controlled trial, 20 patients with MOH were randomly assigned to five days of inpatient withdrawal headache treatment with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (100 mg daily) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/16\">",
"       16",
"      </a>",
"      ]. Evaluable data were available for 18 patients. Of these, 17 had migraine and were overusing triptans. In the first five days, there was a significant decrease in total hours with severe or moderate headache in the group using prednisone (18.1 hours, compared with 36.7 for the placebo group). Given the small study size, these results are not definitive.",
"     </li>",
"     <li>",
"      An open uncontrolled study of 400 outpatients with migraine and MOH evaluated a tapering course of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (60 mg daily on days one and two, 40 mg on days three and four, and 20 mg on days five and six) during analgesic withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/17\">",
"       17",
"      </a>",
"      ]. During the first six days, a reduction in headache frequency was reported for 85 percent of the patients, and none had severe headache attacks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These limited data suggest that high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (100 mg) is beneficial for treating the withdrawal headache in patients with migraine and MOH from triptan overuse. It is not clear whether patients with primary headache types other than migraine (eg, chronic tension-type headache) or those overusing analgesics other than triptans benefit from glucocorticoid bridge therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/18\">",
"     18",
"    </a>",
"    ]. Larger randomized controlled trials are needed to clarify the role of glucocorticoids in the management of MOH.",
"   </p>",
"   <p>",
"    Other glucocorticoid bridge protocols to treat withdrawal headache include intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    100 to 200 mg every 12 hours for two to three days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2,19,20\">",
"     2,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the benefit from glucocorticoids observed in status migrainosus, others have used parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    as bridge therapy to break the cycle of rebound headache [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. Dexamethasone (intravenous or intramuscular) can be started at 8 to 20 mg daily in divided doses, rapidly tapering over two to three days. Hydrocortisone can be started intravenously via a saline drip at 100 mg over 10 min every six hours for 24 hours, then tapered to every eight hours for 24 hours, then every 12 hours for 24 hours, and then a final dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dihydroergotamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     Dihydroergotamine",
"    </a>",
"    (DHE) appears to be beneficial as bridge therapy for MOH. Intravenous (IV) DHE is also recommended as treatment for status migrainosus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repetitive IV DHE (the \"Raskin protocol\") was evaluated originally in a 1986 study that treated 55 patients with chronic intractable migraine headache (including 36 dependent on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      , analgesics,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      , or glucocorticoids) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/23\">",
"       23",
"      </a>",
"      ]. These patients received IV DHE and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      every eight hours. A control group consisted of 54 matched patients (38 drug-dependent) treated with IV diazepam every eight hours. Many of the patients in both groups were overusing opioids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      -caffeine-butalbital preparations. Within 48 hours, 49 DHE-treated patients (89 percent) became headache-free, while only seven diazepam-treated patients (13 percent) became free of headache within three to six days. Since then, other studies have shown benefit of DHE in bridging during analgesic overuse withdrawal.",
"     </li>",
"     <li>",
"      Repetitive IV DHE was also studied in a retrospective report of 300 patients with refractory headache, including 258 who had chronic daily headache [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/24\">",
"       24",
"      </a>",
"      ]. Treatment involved tapering or discontinuation of overused medications (eg, analgesics, barbiturates, caffeine, narcotics, and ergots), repetitive IV DHE and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      , preventive medications, and educational and psychological support. Adjunct medications (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      , among others) were used for withdrawal symptoms of narcotic, barbiturate, and anxiolytic drugs. In addition to DHE, NSAIDs were given as analgesics during withdrawal. Overall, 91 percent of the patients became headache-free, typically within two to three days. The average duration of hospitalization was 7.4 days.",
"     </li>",
"     <li>",
"      Continuous IV DHE may be as effective as repetitive IV DHE. In a retrospective study of 171 patients with refractory headache, the headache-free rates were similar after treatment with continuous IV DHE and repetitive IV DHE (92.5 versus 86.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/25\">",
"       25",
"      </a>",
"      ]. The average hospital stay for both treatment groups was four days. The average length of time to become headache-free was approximately three days for both continuous and repetitive IV DHE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHE can be given intravenously as repetitive or continuous therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repetitive IV DHE treatment is started with IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      (10 mg) given over 30 minutes, followed by a test dose of IV DHE (0.5 mg) over one minute [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/24\">",
"       24",
"      </a>",
"      ]. Therapy is stopped if hypertension, severe nausea, or chest pain occur. Patients who have clinically significant improvement in headache after the test dose are continued on DHE (0.5 mg) every eight hours. Those with persistent headaches without severe nausea are given an additional dose of DHE (0.5 mg) one hour after the first dose, and then DHE (1 mg) every eight hours. Metoclopramide (10 mg) is administered as needed before each infusion of DHE. In patients who have severe nausea, the metoclopramide dose is increased to 20 mg, or the next dose of DHE is decreased to 0.25 mg. The doses of DHE and metoclopramide are adjusted daily based upon headache severity and side effects.",
"      <br/>",
"      <br/>",
"      DHE therapy is continued every eight hours until the patient is headache-free. At that point, IV DHE is tapered to every 12 hours for two or three doses, then discontinued if the patient remains headache-free. Thereafter, any breakthrough headaches are treated with IV DHE every eight hours as needed.",
"     </li>",
"     <li>",
"      Continuous IV DHE is delivered using 3 mg DHE in 1000 mL of normal saline at 42",
"      <span class=\"nowrap\">",
"       mL/hr",
"      </span>",
"      by IV infusion pump, totaling 3 mg of DHE over 24 hours if administered at a constant rate [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       Metoclopramide",
"      </a>",
"      (10 mg IV) is given every eight hours as needed for nausea for approximately six doses. Adjustments in DHE dosage are made to alleviate side effects. The delivery of IV DHE is decreased or interrupted if significant nausea, vomiting, leg cramps, diarrhea, or other undesirable symptoms occur. Once these subside, the DHE dose can usually be continued at a decreased but more tolerable rate. As headaches began to diminish, the dose of continuous IV DHE is decreased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Side effects and contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant adverse reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    (DHE) include nausea, vomiting, dizziness, and somnolence. Uncommon but important reactions include arterial and coronary vasospasm, hypertension, and ventricular arrhythmias.",
"   </p>",
"   <p>",
"    DHE is contraindicated in patients with ischemic vascular disease involving the coronary, cerebrovascular, or peripheral circulations. Other contraindications to DHE include pregnancy, uncontrolled hypertension, hemiplegic or basilar migraine, sepsis, and severe hepatic or renal dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prochlorperazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    may be a useful intervention in the treatment of patients with chronic daily headache with or without analgesic overuse [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study, 135 patients with refractory chronic daily headache, including 95 with analgesic overuse, were treated with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    5 to 10 mg every eight hours, with the dose adjusted up to a maximum of 10 mg every six hours for two to three days according to efficacy and side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/26\">",
"     26",
"    </a>",
"    ]. All analgesics, narcotics, and ergots were discontinued, but preventive medications were maintained or added to the regimen. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (100 mg) was given before sleep to prevent prochlorperazine-related extrapyramidal symptoms (eg, akathisia or dystonia). Prochlorperazine was tapered off by one dose a day if the patient was headache-free or had minimal headache for &gt;24 hours.",
"   </p>",
"   <p>",
"    After IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    treatment, a &ge;50 percent reduction of headache intensity was noted by 121 patients (90 percent), and headache-free status was achieved by 85 (63 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/26\">",
"     26",
"    </a>",
"    ]. The mean inpatient stay was six days (range 3 to 20), and the mean total prochlorperazine used was 98 mg (range 15 to 255 mg). Acute extrapyramidal symptoms occurred in 21 patients (16 percent). These were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    or biperiden.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (lignocaine) for MOH is suggested by a retrospective survey of 71 patients with chronic daily headache and medication overuse [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/27\">",
"     27",
"    </a>",
"    ]. Most patients had been overusing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    . With continuous inpatient lidocaine infusion (2",
"    <span class=\"nowrap\">",
"     mg/minute)",
"    </span>",
"    for a mean duration of eight days (range 3 to 14), improvement or resolution of headache was noted by 64 patients (90 percent). During withdrawal of the overused medication, breakthrough headaches were treated with nonsteroidal antiinflammatory drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    triptans (if not the cause of MOH).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Valproate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    (divalproex sodium, a valproic acid derivative) may be an option in patients who have contraindications to or have failed treatment with DHE [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/28\">",
"     28",
"    </a>",
"    ]. In an uncontrolled study, 10 patients with chronic daily headache",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transformed migraine, with or without medication overuse, were treated with IV valproate beginning with a loading dose of 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    infused over 30 minutes, followed by maintenance doses of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    infused over 15 minutes every eight hours for 12 to 48 hours. All analgesics and triptans were discontinued prior to treatment with valproate, and preventative medications for migraine were begun or continued. Total or near total resolution of headache was reported by four of the 10 patients, while some improvement in headache was reported by eight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38498433\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single retrospective chart review from the United Kingdom reported that open-label intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (lysine acetylsalicylate) was effective for short-term pain relief, assessed one to three hours after administration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/29\">",
"     29",
"    </a>",
"    ]. The study evaluated a series of 168 hospitalized adults with various forms of headache, including 165 with chronic daily headache, 159 who were overusing headache medication at admission, and 129 with a primary headache diagnosis of migraine. IV aspirin (1g) was given from one to 50 doses (median five). Among 113 patients with available outcome information, the subjective effect of aspirin was considered good, moderate, or absent for 27, 58 and 14 percent of patients, respectively. The treatment was well-tolerated, and no serious adverse events were reported.",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is available in Europe and Japan but is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether preventive headache medication should be started at the time of analgesic withdrawal or after withdrawal is controversial, and data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Since most patients will require long-term preventive therapy, we suggest starting such treatment at the time of offending medication withdrawal.",
"   </p>",
"   <p>",
"    In contrast, other authors argue that a preventive drug is unlikely to help during acute analgesic withdrawal, and note that some patients with MOH will not need a prophylactic agent after successful withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study of 43 children (6 to 17 years old) with chronic daily headache and medication overuse, 20 were treated with daily doses of a preventive medication, while 23 received no preventive medication [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/30\">",
"     30",
"    </a>",
"    ]. At one month after withdrawal of analgesics, the proportion of children with a &ge;90 percent reduction in headache was similar for those treated or not treated with daily preventive medication (57 and 50 percent, respectively). The authors concluded that the concurrent use of preventive agents was not necessary during analgesic withdrawal in children with MOH, but that such agents could be added if headaches persist after one month [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Headache preventive therapy should be chosen according to the suspected underlying primary headache disorder (eg, migraine, chronic tension-type headache). Preventive therapy is discussed in detail separately for the major types of primary headache that underlie MOH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7128?source=see_link\">",
"     \"Chronic migraine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18490?source=see_link\">",
"     \"Management of migraine headache in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1433?source=see_link\">",
"     \"Tension-type headache in adults: Preventive treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34744?source=see_link\">",
"     \"Tension-type headache in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43942?source=see_link\">",
"     \"Hemicrania continua\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2968?source=see_link\">",
"     \"New daily persistent headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FOLLOW-UP AND RELAPSE PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to establish or maintain follow-up after the overused medications have been withdrawn [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients frequently return to a pattern of intermittent headaches, which in some individuals may include both full blown migraine attacks and mild to moderate headaches with predominant tension-type features.",
"   </p>",
"   <p>",
"    Long acting nonsteroidal antiinflammatory drugs (NSAIDs) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    sodium or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    are favored for the treatment of mild headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/2\">",
"     2",
"    </a>",
"    ]. Moderate to severe migraine attacks can be treated with triptans,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other migraine abortives. The acute treatment of migraine and tension-type headache is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18490?source=see_link\">",
"     \"Management of migraine headache in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37079?source=see_link\">",
"     \"Tension-type headache in adults: Acute treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34744?source=see_link\">",
"     \"Tension-type headache in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To prevent the redevelopment of MOH, the frequency of acute symptomatic medication usage should be limited, and the rationale for the restriction should be explained to the patient. The use of triptans or over-the-counter combination analgesics should be limited to nine or fewer days a month on average, butalbital-containing analgesics to three or fewer days a month, and NSAIDs to 15 or fewer days a month to prevent MOH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/31\">",
"     31",
"    </a>",
"    ]. The more restrictive limits on butalbital-containing analgesics are due to their high potential for MOH. In general, it is best to avoid the use of opioids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    butalbital for the regular management of primary headache disorders.",
"   </p>",
"   <p>",
"    Proper treatment of MOH and relapse prevention requires recognition of the elements that may contribute to and underlie its development and perpetuation. Coexistent anxiety should be properly managed if present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=see_link&amp;anchor=H6#H6\">",
"     \"Medication overuse headache: Etiology, clinical features, and diagnosis\", section on 'Biobehavioral factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term success of withdrawal from MOH depends, in part, on the type of primary headache and the type of overused medication. Most relapses happen in the first year after withdrawal. These points are illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted earlier, a meta-analysis of 17 studies and 1101 patients with MOH found that the success rate for withdrawal therapy at one to six months was 72 percent, where treatment success was defined as either no headaches or a reduction in headache days of &gt;50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Withdrawal of the overused medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a study with prospective data collected from 240 patients with MOH who were treated with drug withdrawal and preventive therapy, the one-year rate of treatment success (defined as absence of chronic headache and medication overuse) was 57 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/32\">",
"       32",
"      </a>",
"      ]. Independent predictors of unfavorable treatment outcome at one year were a higher frequency of primary headache,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      overuse, and a greater degree of headache-related disability at the time of MOH diagnosis.",
"     </li>",
"     <li>",
"      In a prospective study of 96 patients with MOH, complete data sets at four years were available for 75 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/33\">",
"       33",
"      </a>",
"      ]. The relapse rate at six months, one year, and four years was 31, 41, and 45 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/33\">",
"       33",
"      </a>",
"      ]. Patients with underlying migraine headache had a lower relapse rate than those with tension-type headache or combined migraine and tension-type headache, but small numbers prevent definitive conclusions.",
"     </li>",
"     <li>",
"      In a retrospective report that analyzed outcomes for 67 patients with MOH after multidisciplinary headache treatment at a tertiary center, the reduction in total headache frequency for those with underlying tension-type headache and those with underlying migraine was 50 and 72 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17161/abstract/34\">",
"       34",
"      </a>",
"      ]. These findings suggest that patients with background migraine have a better outcome following withdrawal from MOH than those with underlying tension-type headache.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=see_link\">",
"       \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following are the basic steps in the management of medication overuse headache (MOH):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient education (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Patient education'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Withdrawal of the offending medication (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Withdrawal of the overused medication'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Bridge (transitional) therapy, aimed at symptomatic relief during medication withdrawal (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Bridge therapy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Establishment of a headache treatment regimen covering acute and preventive care appropriate for the underlying primary headache disorder (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Preventive therapy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Follow up and relapse prevention (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Follow-up and relapse prevention'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is important to educate patients about the detrimental effects of analgesic overuse, particularly that analgesics have the potential to cause MOH, and that analgesic overuse can negate the effectiveness of headache preventive measures. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Patient education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with MOH, we suggest abrupt withdrawal of the offending medication rather than a gradual taper (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This can usually be managed in the outpatient setting. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Outpatient and inpatient strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With overuse of barbiturates, opioids, or benzodiazepines, the pace of withdrawal depends on the amount and frequency of usage. Abrupt withdrawal is done routinely in clinical practice if the dosage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      frequency of administration are not too high. However, we suggest a gradual taper when these agents (particularly barbiturates or benzodiazepines) are being used frequently or at high doses (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The taper can usually be accomplished in two to four weeks. When butalbital is stopped abruptly or when high doses are being used, we recommend a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      taper for seizure prophylaxis (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Our suggested regimen is phenobarbital 30 mg twice a day for two weeks, followed by 15 mg twice a day for two weeks. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Outpatient and inpatient strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When there is concern for opioid withdrawal symptoms, we suggest treatment with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      patch for one to two weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Outpatient and inpatient strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inpatient withdrawal with medical monitoring in the first several days may be preferred for some patients who have been using high doses of barbiturates, opioids, and benzodiazepines. Inpatient management may also be preferable for patients with weak social support, medical or psychiatric comorbidities, poor motivation, and those who have previously failed outpatient drug withdrawal. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Outpatient and inpatient strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with MOH undergoing withdrawal of the offending medication, we suggest use of bridge therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Bridge therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For outpatients, our preferred choices for bridge therapy are long acting nonsteroidal antiinflammatory drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      ) or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Naproxen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Glucocorticoids'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      For inpatients, our preferred choices for bridge therapy are intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"       dihydroergotamine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      , intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      , intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Dihydroergotamine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Prochlorperazine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Valproate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Glucocorticoids'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with MOH and an identified underlying primary headache disorder (eg, migraine or tension-type headache), we suggest starting preventive treatment at the same time as withdrawing the offending medication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Preventive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To prevent MOH relapse, triptan or over-the-counter combination analgesic use should be limited to nine or fewer days a month on average, and NSAIDs to 15 or fewer days a month. Butalbital-containing analgesics and opioids should be avoided because of their high risk for MOH. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Follow-up and relapse prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/1\">",
"      Abrams BM. Medication overuse headaches. Med Clin North Am 2013; 97:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/2\">",
"      Boes CJ, Black DF, Dodick DW. Pathophysiology and management of transformed migraine and medication overuse headache. Semin Neurol 2006; 26:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/3\">",
"      Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: clinical implications. Headache 2006; 46 Suppl 4:S202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/4\">",
"      Rossi P, Di Lorenzo C, Faroni J, et al. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia 2006; 26:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/5\">",
"      Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004; 3:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/6\">",
"      Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 2006; 26:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/7\">",
"      Mathew NT, Kurman R, Perez F. Drug induced refractory headache--clinical features and management. Headache 1990; 30:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/8\">",
"      Katsarava Z, Jensen R. Medication-overuse headache: where are we now? Curr Opin Neurol 2007; 20:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/9\">",
"      Obermann M, Katsarava Z. Management of medication-overuse headache. Expert Rev Neurother 2007; 7:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/10\">",
"      Freitag FG, Lake A 3rd, Lipton R, et al. Inpatient treatment of headache: an evidence-based assessment. Headache 2004; 44:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/11\">",
"      Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/12\">",
"      Mathew NT. Amelioration of ergotamine withdrawal symptoms with naproxen. Headache 1987; 27:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/13\">",
"      Pascual J, Berciano J. [Daily chronic headache in patients with migraine induced by abuse of ergotamine-analgesics: response due to a protocol of outpatient treatment]. Neurologia 1993; 8:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/14\">",
"      Smith TR. Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache 2002; 42:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/15\">",
"      B&oslash;e MG, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. Neurology 2007; 69:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/16\">",
"      Pageler L, Katsarava Z, Diener HC, Limmroth V. Prednisone vs. placebo in withdrawal therapy following medication overuse headache. Cephalalgia 2008; 28:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/17\">",
"      Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 2000; 20:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/18\">",
"      Diener HC. How to treat medication-overuse headache: prednisolone or no prednisolone? Neurology 2007; 69:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/19\">",
"      Young WB. Medication Overuse Headache. Curr Treat Options Neurol 2001; 3:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/20\">",
"      Rozen TD. Migraine Headache: Immunosuppressant Therapy. Curr Treat Options Neurol 2002; 4:395.",
"     </a>",
"    </li>",
"    <li>",
"     Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Wolff's headache and other head pain, Silberstein SD, Lipton RB, Dalessio DJ (Eds), Oxford University Press, New York 2001. p.121.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/22\">",
"      Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/23\">",
"      Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986; 36:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/24\">",
"      Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990; 30:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/25\">",
"      Ford RG, Ford KT. Continuous intravenous dihydroergotamine in the treatment of intractable headache. Headache 1997; 37:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/26\">",
"      Lu SR, Fuh JL, Juang KD, Wang SJ. Repetitive intravenous prochlorperazine treatment of patients with refractory chronic daily headache. Headache 2000; 40:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/27\">",
"      Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia 2003; 23:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/28\">",
"      Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache 2002; 42:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/29\">",
"      Weatherall MW, Telzerow AJ, Cittadini E, et al. Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache. Neurology 2010; 75:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/30\">",
"      Kossoff EH, Mankad DN. Medication-overuse headache in children: is initial preventive therapy necessary? J Child Neurol 2006; 21:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/31\">",
"      Garza I, Swanson JW. Answers to frequently asked questions about migraine. Mayo Clin Proc 2006; 81:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/32\">",
"      Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, et al. Medication overuse headache: clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia 2007; 27:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/33\">",
"      Katsarava Z, Muessig M, Dzagnidze A, et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005; 25:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17161/abstract/34\">",
"      Zeeberg P, Olesen J, Jensen R. Efficacy of multidisciplinary treatment in a tertiary referral headache centre. Cephalalgia 2005; 25:1159.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3341 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17161=[""].join("\n");
var outline_f16_48_17161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATIENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WITHDRAWAL OF THE OVERUSED MEDICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Outpatient and inpatient strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Withdrawal symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BRIDGE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Naproxen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tizanidine plus nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dihydroergotamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Side effects and contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prochlorperazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lidocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Valproate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38498433\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FOLLOW-UP AND RELAPSE PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7128?source=related_link\">",
"      Chronic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43942?source=related_link\">",
"      Hemicrania continua",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18490?source=related_link\">",
"      Management of migraine headache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=related_link\">",
"      Medication overuse headache: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2968?source=related_link\">",
"      New daily persistent headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=related_link\">",
"      Overview of chronic daily headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=related_link\">",
"      Patient information: Headache treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37079?source=related_link\">",
"      Tension-type headache in adults: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1433?source=related_link\">",
"      Tension-type headache in adults: Preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34744?source=related_link\">",
"      Tension-type headache in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_48_17162="Polyarticular onset juvenile idiopathic arthritis: Management";
var content_f16_48_17162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Polyarticular onset juvenile idiopathic arthritis: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/48/17162/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/48/17162/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/48/17162/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/48/17162/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/48/17162/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/48/17162/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/48/17162/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarticular onset juvenile idiopathic arthritis (formerly called polyarticular onset juvenile rheumatoid arthritis) is a subset of juvenile idiopathic arthritis (JIA) that is defined by the presence of more than four affected joints during the first six months of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/1\">",
"     1",
"    </a>",
"    ]. In the newer proposed nomenclature, this disease, which comprises 20 to 30 percent of patients with JIA, is included in the group termed childhood polyarthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=see_link\">",
"     \"Classification of juvenile arthritis (JRA/JIA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of polyarticular onset JIA will be reviewed here. The clinical manifestations and diagnosis of polyarticular onset JIA, systemic onset JIA, and pauciarticular onset JIA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=see_link\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THERAPEUTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy is directed toward treating the underlying inflammation of juvenile idiopathic arthritis (JIA), and preventing complications associated with JIA (eg, joint damage) or the adverse effects of its treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/2\">",
"     2",
"    </a>",
"    ]. Medications used in the treatment of polyarticular onset JIA have various mechanisms of action (sometimes unknown), but all suppress inflammation. Medications include first-line nonsteroidal inflammatory agents (NSAIDs) and second-line drugs referred to as disease-modifying antirheumatic drugs (DMARDs) that include immunomodulators, biologic agents, and glucocorticoids.",
"   </p>",
"   <p>",
"    Although physical therapy plays an important role in the rehabilitation of any child with polyarticular disease, range of motion and stretching exercises are of limited benefit in the face of ongoing joint inflammation. Furthermore, the efficacy and availability of the newer therapeutic agents (such as the biologic agents) has allowed many children to regain full function in a short period of time. Nonetheless, any child with persistent weakness or flexion contractures should be referred for physical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL DRUG THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial drug therapy for children with polyarticular JIA should be aggressive in order to control the inflammatory process and relieve symptoms as quickly as possible while minimizing drug side effects. Although many parents and clinicians voice fear of unknown side effects from medication, years of experience make it clear that there is far more to fear from the damage known to be caused by polyarticular JIA. The belief statement that children often \"grow out of JIA\" is incorrect and may lead to delays in appropriate therapy and poor outcomes. It is essential that clinicians make families aware of the fact that children with polyarticular JIA are unlikely to outgrow their disease, since this myth may heavily influence the family&rsquo;s understanding of the risk to benefit ratio of medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) traditionally have been the preferred first-line drugs in patients with mild disease and for symptomatic relief [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These medications reach full efficacy within two to three months, but usually start to relieve symptoms within a few days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/3\">",
"     3",
"    </a>",
"    ]. Those who have not responded to initial NSAID therapy within three weeks should have the initial NSAID discontinued and a second NSAID begun or, if warranted, they should be advanced to a disease modifying antirheumatic drug (DMARD). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Disease modifying antirheumatic drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Unfortunately, there is no way to predict which NSAID is most likely to benefit an individual patient. A process of trial and error must be used while keeping expectations appropriate; patients should be aware that NSAIDs are useful for relieving discomfort, but they do not delay or prevent joint damage in JA. Long-term safety data on NSAIDs are needed because potential adverse effects, especially cardiovascular events, may not appear until adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/5\">",
"     5",
"    </a>",
"    ]. However, an email survey of the pediatric rheumatology community found no recognized cases of children treated with NSAIDs who developed premature myocardial infarctions. These agents are important for the symptomatic relief of pain and stiffness, but they do not prevent joint destruction. Thus, any child with continuing active disease should be promptly advanced to a disease modifying agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DISEASE MODIFYING ANTIRHEUMATIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is rare for NSAIDs alone to control the inflammatory process of polyarticular disease. Thus, a second-line drug, often referred to as a disease modifying antirheumatic drug (DMARD), is usually begun in all but the mildest patients while waiting for benefits from NSAIDs, since chronic joint changes may occur if arthritis remains active. The initiation of DMARDs, including immunomodulatory, biologic, and antiinflammatory agents should not be delayed excessively. Ongoing trials are examining the risks and benefits of starting DMARDs coincident with, or even before, initiating NSAIDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the DMARDs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    has been the standard therapy for children with polyarticular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. It is an immunomodulator and acts as an inhibitor of purine synthesis, though at the doses used to treat JIA, other mechanisms of action appear to account for its effects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/10\">",
"     10",
"    </a>",
"    ]. Methotrexate is used at a dose of 10 to 15",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    body surface area (BSA) per week. At this dose, it acts as an antiinflammatory agent rather than as a cytotoxic drug. Methotrexate is effective for many patients, but it does not work quickly, usually taking four to eight weeks before demonstrating its benefits. In addition, children with longer disease duration, negative ANA titers, higher level of disability, and arthritis present in both wrists are less likely to respond to methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/11\">",
"     11",
"    </a>",
"    ]. Use of a biologic agent should be considered if a more rapid response is necessary. (See",
"    <a class=\"local\" href=\"#H9390825\">",
"     'Biologic agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The question of whether treatment of early polyarticular JIA with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    alone or methotrexate in combination with a biologic agent and systemic glucocorticoid is effective was examined in a randomized trial of 85 children aged 2 to 16 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/12\">",
"     12",
"    </a>",
"    ]. Children were randomly assigned to combination therapy (n = 42) with methotrexate (0.5",
"    <span class=\"nowrap\">",
"     mg/kg/week",
"    </span>",
"    subcutaneously, maximum dose 40 mg),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (0.8",
"    <span class=\"nowrap\">",
"     mg/kg/week",
"    </span>",
"    subcutaneously, maximum dose 50 mg), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    orally, maximum dose 60 mg, tapered off by 17 weeks) or methotrexate alone (n = 43) with etanercept and prednisolone placebos. Both therapies were moderately effective, although there was a trend toward greater efficacy in the initial combination group compared with methotrexate monotherapy that was significant only at the six month time point. At four months, 30 children in the combination therapy group had inactive disease, compared with 19 in the methotrexate only group. By six months, only 17 and 9 had inactive disease in the combination and methotrexate groups, respectively. At 12 months, 9 of the 17 children in the combination group had attained clinical remission and the remainder had inactive disease. In comparison, three children were in clinical remission and four had inactive disease at 12 months in the methotrexate group. Five children in the combination group withdrew over the course of the study, three due to adverse events, one because of an inadequate response, and one due to a disease flare. Eleven children withdrew from the methotrexate group, four due to an adverse event, five because of an inadequate response, one due to a disease flare, and one due to a fear of needles.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is generally ineffective for the treatment of axial arthritis, as is found in ankylosing spondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, it is important to recognize that children with seronegative spondyloarthropathies are distinct from children with polyarthritis so that they may be advanced to appropriate biologic therapy without the delay and possible toxicity associated with a trial of methotrexate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=see_link\">",
"     \"Spondyloarthropathy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    are many and include leukopenia or thrombocytopenia, elevation of hepatic transaminases (especially if ethanol is consumed), and the rare development of pulmonary hypersensitivity reactions, nodulosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/14\">",
"     14",
"    </a>",
"    ], and possibly malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/15\">",
"     15",
"    </a>",
"    ]. In practice, however, dose-limiting side effects are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/16\">",
"     16",
"    </a>",
"    ]. Similarly, although long-term data in children are limited, meta-analyses in adults suggest that the chronic use of methotrexate in rheumatoid arthritis is associated with a minimally increased risk of infections, no increase in the incidence of opportunistic infections, no clear increase in the risk of malignancies, and an apparent advantage in longevity and decreased cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in adults, malignancies have been described in association with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in children with arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/15\">",
"     15",
"    </a>",
"    ] Methotrexate is also associated with the rare development of nodulosis in children with JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study examined the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    regimens at two medical centers in the same geographic region, one of which started patients on an initial dose of &gt;0.5",
"    <span class=\"nowrap\">",
"     mg/kg/week",
"    </span>",
"    (similar, but not identical to 15",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    and the other which began patients on &le;0.5",
"    <span class=\"nowrap\">",
"     mg/kg/week",
"    </span>",
"    (similar to 10",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/18\">",
"     18",
"    </a>",
"    ]. The high-dose group was more likely to have elevated liver enzymes, but was no more likely to have a decreased active joint count.",
"   </p>",
"   <p>",
"    Genotyping may help predict the risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    toxicity. Single-nucleotide polymorphisms (SNPs) in genes within the methotrexate metabolic pathway, such as the C677T allele of the methylenetetrahydrofolate reductase gene, are associated with increased methotrexate adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However at present these tests are not routinely available.",
"   </p>",
"   <p>",
"    Any evidence of significant toxicity requires a decrease or discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Some side effects such as glossitis and macrocytic anemia are often avoided by the addition of supplemental",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , which should be started at the same time as the methotrexate. Whether high doses of folic acid might also diminish the effectiveness of methotrexate, or cause side effects, are topics of debate. Published articles report conflicting results regarding potential antagonism of the beneficial effects of methotrexate by folate supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/21\">",
"     21",
"    </a>",
"    ]. Similarly, studies have shown both an increase [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/22\">",
"     22",
"    </a>",
"    ] and a decrease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/23\">",
"     23",
"    </a>",
"    ] in the incidence of cancer among people receiving folic acid supplementation. The effects appear to depend upon a variety of factors, including characteristics of the specific population studied [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/24\">",
"     24",
"    </a>",
"    ]. No adverse effects have been demonstrated to date in children receiving supplemental folic acid to minimize methotrexate toxicity. Folic acid supplementation is recommended for all children with JIA receiving methotrexate, given the beneficial effects noted and the lack of convincing contrary data.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is typically continued for six months after induction of remission. A prospective, open, randomized trial of methotrexate withdrawal after remission found no difference in relapse rates between 12-month versus 6-month withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/25\">",
"     25",
"    </a>",
"    ]. Both groups experienced a roughly 60 percent rate of relapse, although patients with higher levels of the phagocyte activation marker myeloid-related proteins 8 and 14 heterocomplex",
"    <span class=\"nowrap\">",
"     (MRP8/14)",
"    </span>",
"    were at greater risk of relapse after discontinuation of methotrexate. These tests are not routinely available and hence of limited utility. Nonetheless, the study does raise the question of whether the appropriate response is not to discontinue methotrexate at all, since there is a risk of ongoing joint damage with each relapse. Further studies are needed to identify biomarkers predicative of future relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9390825\">",
"    <span class=\"h2\">",
"     Biologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is customary to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    before biologic agents for children with polyarthritis (except those with seronegative spondyloarthropathies), because of the risks and costs associated with these agents compared with methotrexate. However, biologic agents have a more rapid onset of action and appear to be more efficacious than methotrexate. Thus, many pediatric rheumatologists start with a biologic response modifier before or concurrent with methotrexate in particularly severe cases of polyarthritis. In addition, some centers are using biologic agents early, even in less severe cases, with the goal of preventing additional joint damage during the period necessary for methotrexate to take effect. Labeling indications for both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    (anti-tumor necrosis factor [TNF] therapies) currently do not require failure to respond to methotrexate before their use in children with JIA. Ongoing trials should help clarify the optimum approach to new-onset polyarthritis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Methotrexate'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     TNF inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNF inhibitors are one class of biologic agents currently being used in patients with JIA. They are often efficacious, but are associated with an increased risk of infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. There were initial concerns about a possible association between treatment with TNF inhibitors and malignancy, but subsequent data has suggested that the risk of malignancy is associated with autoimmunity rather than the medications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/29\">",
"     29",
"    </a>",
"    ]. Nonetheless, they often provide rapid control of otherwise disabling arthritis restoring quality of life and preventing further joint destruction. We suggest that TNF inhibitors be used in patients with severe disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Citing concerns about possible carcinogenesis, the Food and Drug Administration (FDA) performed a Safety Review of TNF inhibitors and concluded that there is an increased risk of lymphoma and other cancers associated with the use of these drugs in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the majority of patients with malignancies were children with inflammatory bowel disease who were receiving other immunosuppressive agents in addition to intravenous TNF inhibitors. For children with arthritis, virtually all of the malignancies occurred in patients who received additional immunosuppressive agents, most commonly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/27\">",
"     27",
"    </a>",
"    ]. This raises the question of whether such combination therapy increases the risks for children with arthritis.",
"   </p>",
"   <p>",
"    Information regarding the risk of malignancy is included in the boxed warning for biologic agents and patients and parents should be aware of this association. Discussions with health care providers should review the risks and potential benefits of TNF inhibitors, as well as the risks and benefits of alternative treatments.",
"   </p>",
"   <p>",
"    In adults, TNF-inhibitors increase the risk of opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/31\">",
"     31",
"    </a>",
"    ]. In children, there is also an increased risk of fungal infections, especially in endemic areas of histoplasmosis such as the Ohio and Mississippi River valleys, with the use of anti-TNF agents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/32\">",
"     32",
"    </a>",
"    ]. Clinicians in areas of other endemic fungal infections should monitor their patients appropriately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    (Enbrel&reg;), a fusion protein containing tumor necrosis factor (TNF) receptor 2 and the Fc domain of IgG1, has been effective in many children with resistant polyarticular disease, including those under four years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. Dramatic improvements may be seen within weeks of starting therapy, with benefits persisting during years of use. Most patients respond promptly, although some may have a delayed clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one open-label study of 69 children, for example, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    at a dose of 0.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice a week resulted in a response (defined as &gt;30 percent improvement) in nearly 75 percent of patients within three months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/39\">",
"     39",
"    </a>",
"    ]. A flare subsequently occurred in 28 percent of those continuing to receive etanercept versus 81 percent in whom placebo was substituted in a randomized and blinded fashion. Thus, in most children, the effects of etanercept cease within a few weeks of its discontinuation.",
"   </p>",
"   <p>",
"    Subsequent studies reviewed the safety and efficacy of long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    therapy in the 58 patients who elected to continue therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At a four-year follow-up, 24 of the 69 original patients had withdrawn from the study because of lack of efficacy, adverse reactions,",
"      <span class=\"nowrap\">",
"       clinician/parental",
"      </span>",
"      choice, or",
"      <span class=\"nowrap\">",
"       protocol/study",
"      </span>",
"      issues, or had been lost to follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/40\">",
"       40",
"      </a>",
"      ]. The remaining 34 patients were evaluated after receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      for four or more years. Of the 28 patients who required corticosteroid therapy, 23 were able to reduce their steroid dose to &le;5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      equivalent. Of the 32 patients who were evaluated using the American College of Rheumatology (ACR) Pediatric criteria for improvement and disease activity [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/42\">",
"       42",
"      </a>",
"      ], 30 had improvement of their symptoms and a decrease in disease activity. Eight patients had serious infections during the first four years of treatment, while none had malignancies.",
"     </li>",
"     <li>",
"      At an eight-year follow-up, 20 of the 58 patients remained on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/41\">",
"       41",
"      </a>",
"      ]. These patients continued to demonstrate marked improvement as indicated by the ACR Pediatric 70 response achieved by 60 percent of patients. However, there was no significant reduction from baseline in the use of NSAIDs or corticosteroids. Of the 38 (of the original 58) who withdrew from the study, seven did so for lack of efficacy, four for side effects, and eight for \"refusal\". An additional nine serious adverse events were reported after the first follow-up study (six cases of disease flare, and one case each of pyelonephritis, arthralgia, and allergic reaction). Between the fourth and eighth year of follow-up, a single case of pyelonephritis was the only additional infection reported.",
"      <br/>",
"      <br/>",
"      The relatively high rate of infection may in part be due to the use of etanercept in combination with other immunosuppressive drugs in these children with severe refractory disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another small pilot study, bone mineral status improved in patients who had responded to and continued",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    treatment for more than one year compared to those who failed to respond [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition, anti-TNF therapy appears to improve growth velocity in patients with delayed growth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Improved linear growth, bone mineralization, and body composition were seen in another small study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/46\">",
"     46",
"    </a>",
"    ]. These effects are probably due to decreased inflammation resulting from control of arthritis. In general, similar effects to those of etanercept should be expected from other TNF antagonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    As the oldest of the TNF-inhibitors in clinical use, there is a relatively large amount of data regarding the long-term safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/47\">",
"     47",
"    </a>",
"    ]. In patients who remain on therapy, the clinical benefits are substantial, and significant toxicity is uncommon. Symptoms improve in a sizable proportion of patients with refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/34\">",
"     34",
"    </a>",
"    ] and growth improves [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/48\">",
"     48",
"    </a>",
"    ]. No cases of malignancy have been reported in these follow-up studies of children treated with etanercept for JIA. There have been two reports of inflammatory bowel disease in JIA patients treated with etanercept, although these children might well have had unrecognized inflammatory bowel disease at the time they were diagnosed with polyarthritis, rather than bowel disease caused by etanercept [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The available data favor the use of biologics which block TNF compared with other therapeutic regimens in children with refractory polyarticular JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/47,51,52\">",
"     47,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues, such as whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , with its potentially faster onset of action and greater efficacy, should be used before",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , remain to be resolved. There is also evidence that the combination of etanercept and methotrexate is synergistic for the treatment of arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/35\">",
"     35",
"    </a>",
"    ]. These considerations must be balanced against the increased risk of opportunistic infections with the use of TNF-inhibitors, especially when used as part of multiple drug therapy. In addition, there is not yet a clear answer to the question of whether benefits of biologic agents justify their significantly higher costs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/53\">",
"     53",
"    </a>",
"    ]. Ongoing studies aimed at identifying markers of response and risk factors for adverse events should improve selection of appropriate candidates for the use of biologic agents and help answer and resolve some of these important issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Adalimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    (Humira&reg;) is a fully humanized monoclonal anti-TNF antibody, which is administered either weekly or every other week as a single subcutaneous injection. Preliminary experience has suggested that adalimumab is effective in some children who responded inadequately to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In 2008,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    was approved by the FDA for the treatment of moderate to severe JIA in patients four years or older. Approval was based upon data from a trial of 171 patients who were stratified into two groups: those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and those not treated with methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/54\">",
"     54",
"    </a>",
"    ]. After an open-label lead-in phase of 16 weeks with adalimumab therapy, patients with an ACR Pedi 30 response were randomly selected to receive adalimumab at a dose of 24 mg per m2 every other week or placebo for an additional 32 weeks. In the second phase of the study, patients who received adalimumab compared to those who received placebo experienced fewer disease flares regardless of whether they received methotrexate (37 versus 65 percent) or not (43 versus 71 percent). In this trial, severe adverse effects included neutropenia and infections (herpes simplex and zoster, urinary tract infection, pneumonia, and pharyngitis). No malignancies were reported.",
"   </p>",
"   <p>",
"    In addition to the above reported adverse effects, there is greater immediate pain at the site of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    injection when compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , but this is generally an inconvenience that children find bearable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    (Remicade&reg;), a chimeric mouse-human monoclonal antibody with affinity for TNF-alpha, may have similar efficacy to that seen with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    . It is not approved by the FDA for treatment of JIA. It has been used in clinical trials in patients who are refractory to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and is undergoing study in combination therapy with methotrexate for recent-onset polyarticular JIA.",
"   </p>",
"   <p>",
"    In a multicenter randomized trial, 122 children with polyarticular juvenile idiopathic arthritis who had not responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy were randomly assigned to one of two treatment regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/55\">",
"     55",
"    </a>",
"    ]. Group 1 received placebo and methotrexate at weeks 0, 2, and 6, followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    plus methotrexate at weeks 14, 16, and 20 and then every 8 weeks. Group 2 received infliximab 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    plus methotrexate at weeks 0, 2, 6, and 14; placebo at week 16, followed by infliximab 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at week 20 and then every 8 weeks. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the first 14 weeks, there was a trend towards greater improvement in the ACR Pediatric criteria among patients who initially received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      compared to those who received placebo (64 versus 49 percent). However, this did not reach statistical significance.",
"     </li>",
"     <li>",
"      By week 16 when the placebo treated patients crossed over to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      6",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      73 percent of all patients had achieved a 30 percent improvement in the ACR Pediatric criteria.",
"     </li>",
"     <li>",
"      By week 52, 70 and 52 percent of all patients had achieved a 50 and 70 percent improvement in the ACR Pediatric criteria, respectively.",
"     </li>",
"     <li>",
"      Antibodies to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      developed in 25 percent of the 102 patients who were evaluated. A higher proportion of antibody formation was seen in the 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      compared to the 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      infliximab groups (38 versus 12 percent). Similarly, overall adverse events were more frequent among those who received 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      infliximab versus those receiving 6",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"     </li>",
"     <li>",
"      Adverse events were greater in patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      compared to those who received placebo. They included infection (67 versus 47 percent) and infusion-associated reactions (35 versus 8 percent), such as vomiting, fever, headache, and hypotension. There were two deaths; one patient died during the placebo phase and one patient receiving the lower dose of infliximab also died.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seventy-eight patients (64 percent) from this study entered an open-label treatment extension [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/56\">",
"     56",
"    </a>",
"    ]. Eight children discontinued",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    due to lack of efficacy, and 19 patients stopped the drug due to reasons unrelated to efficacy or safety. By week 204, 40 and 33 percent had a 50 and 70 percent improvement in the ACR Pediatric criteria, respectively. Infusion reactions continued to occur at a similar rate (32 percent) as in the randomized phase of the study. These reactions occurred more frequently in those positive for antibodies to infliximab.",
"   </p>",
"   <p>",
"    One small observational, uncontrolled study compared the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (14 patients) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (10 patients) in children with polyarticular juvenile idiopathic arthritis who had not responded to a combination of DMARDs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/57\">",
"     57",
"    </a>",
"    ]. There were more withdrawals from the infliximab group than from the cohort receiving etanercept (five children versus one, respectively), but the proportion of good responses among patients who completed a year of anti-TNF therapy was similar in the two groups (ACR pediatric 50 improvement of 80 to 90 percent). Infusion reactions were the most common reason for withdrawal for those receiving infliximab (3 of 5). One boy had a systemic illness shortly after the second infusion with features suggestive of macrophage activation syndrome, and one girl developed alopecia and anti-double stranded DNA antibodies that led to discontinuation of infliximab therapy after six months.",
"   </p>",
"   <p>",
"    In a randomized, open-label study three regimens were compared for the treatment of recent-onset polyarticular JIA:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (n = 19), methotrexate alone (n = 20), and a DMARD combination (methotrexate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    ; n = 20) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/58\">",
"     58",
"    </a>",
"    ]. American College of Rheumatology pediatric 75 percent improvement (ACR pedi 75) was achieved in all patients on infliximab plus methotrexate, 65 percent on the DMARD combination, and 50 percent on methotrexate alone. Inactive disease was attained in 68, 40, and 25 percent of the same treatment groups, respectively.",
"   </p>",
"   <p>",
"    Most centers report a similarly increased incidence of side effects in children treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    relative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    . In general, etanercept is better tolerated and more easily administered than infliximab. High doses of infliximab (&gt;5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    may be more effective than the standard dose of infliximab (3",
"    <span class=\"nowrap\">",
"     mg/kg/dose),",
"    </span>",
"    but they may also carry increased risks. Further trials are required to characterize the efficacy and safety of various dosing regimens of infliximab in JIA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other biologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other biologic agents that are options in patients with refractory disease include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Abatacept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    blocks T cell costimulation, which interferes with proinflammatory messages being passed to and from T cells. Abatacept (Orencia) is approved by the United States FDA for the treatment of JIA. The pivotal study demonstrated a decrease in the rate of arthritis flares with abatacept compared to placebo in a trial of 190 patients between 6 and 17 years of age who had a history of active disease in five joints and an inadequate response to at least one DMARD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/59\">",
"     59",
"    </a>",
"    ]. In this study, 170 patients who completed the open-label lead-in period of four months of abatacept therapy and had a positive response to the drug were randomly selected to continue to receive 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of abatacept every 28 days or placebo for an additional six months or until their arthritis flared. Patients who received abatacept compared to those who received placebo experienced fewer disease flares (20 versus 53 percent). There was no difference in the frequency of adverse events between the two groups. Greater improvements were also seen in health-related quality of life measures, particularly",
"    <span class=\"nowrap\">",
"     pain/discomfort",
"    </span>",
"    and sleep, in the abatacept group compared with the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    (Rituxan&reg;), a chimeric anti-CD20 monoclonal antibody, has been approved for the treatment of adult onset rheumatoid arthritis (RA) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Although most subsets of JIA are not the same disease as adult RA, in limited experience, adolescents with RF positive disease unresponsive to other agents have benefited from rituximab. The utility of this agent in other settings is unknown. There are anecdotes of its successful use in other subtypes of JIA, but there are no reliable data to date regarding its efficacy in patients with refractory JIA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin has been studied in polyarticular JIA. While it appears to have some efficacy, its effects are short-lived and insufficient to justify its cost and potential toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9391095\">",
"    <span class=\"h2\">",
"     Additional agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional agents that may be useful in some patients with polyarticular JIA include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    . Systemic glucocorticoids are not recommended, but intraarticular glucocorticoids are used.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and gold compounds are rarely used now that more effective agents are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9390671\">",
"    <span class=\"h3\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    has been shown to be beneficial for many children with polyarticular JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/64-67\">",
"     64-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This utility was illustrated in a randomized, placebo-controlled, double-blind, 24 week study of 69 patients with oligoarticular and polyarticular JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/65\">",
"     65",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    , compared to placebo, resulted in significant improvement as determined by overall articular severity score, global assessments, and laboratory parameters. Adverse events, which were found in one-third of patients, were transient or reversible upon cessation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent study reported the clinical status of this cohort of patients at a median follow-up of nine years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/67\">",
"     67",
"    </a>",
"    ]. Patients who were in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    treatment group compared to those treated with placebo appeared to require less intensive DMARD treatment based upon a shorter duration of sulfasalazine (2.5 versus 5.2 years) and a trend to less use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and other DMARDs. At follow-up assessment, outcome scores were better in the group treated with sulfasalazine compared to the control group. However, more than one-third of patients in both groups reported long periods of noncompliance with therapy, which significantly impacted patient outcomes.",
"   </p>",
"   <p>",
"    In using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , families must be warned of the possible development of rare severe reactions seen with sulfa drugs (eg, Stevens-Johnson syndrome). White count, platelet count, and liver enzymes must be periodically monitored as well. Sulfasalazine does not prevent chronic changes and, therefore, should not be relied upon in erosive disease. For those with erosive disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or anti-TNF therapies are preferable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9391133\">",
"    <span class=\"h3\">",
"     Leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    , an immunomodulator that inhibits pyrimidine synthesis, has been shown to be safe and effective in adults with rheumatoid arthritis. Although not FDA approved for pediatric use, efficacy in JIA has been reported, but has not been shown to be superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/9,68,69\">",
"     9,68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized study of 94 children with JIA, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    resulted in clinically meaningful improvements [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients were treated initially with either methotrexate or leflunomide in a double-blinded fashion for 16 weeks, with blinded treatment extended for an additional 32 weeks. Both medications resulted in improved articular severity score, global assessments (clinician and patient), and erythrocyte sedimentation rate. Methotrexate appeared to be more effective than leflunomide as a greater percentage of children demonstrated clinical improvement, although the dose of leflunomide used in this study was somewhat low. The most common adverse events for both medications included gastrointestinal symptoms (abdominal pain, nausea, vomiting or diarrhea), headache, and nasopharyngeal symptoms (eg, pharyngitis). Children on either medication need to be carefully monitored for evidence of hepatic toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term high dose oral glucocorticoids should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in children with polyarticular onset JIA because of the high incidence of side effects, particularly growth retardation and osteoporosis. Some have advocated pulsed doses of glucocorticoids as being effective in controlling inflammation without causing side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/33\">",
"     33",
"    </a>",
"    ]. Others, however, have noted that over 20 percent of patients receiving pulsed-dose steroids had one or more adverse reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/33\">",
"     33",
"    </a>",
"    ]. Nevertheless, short-term use of low dose glucocorticoids (less than 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent) may provide substantial benefits for the child who is otherwise incapacitated by arthritis without causing excessive complications. Most clinicians have found anti-TNF agents to provide an equally rapid clinical response in children with severe JIA. Children with JIA severe enough to warrant consideration of glucocorticoid may in any case ultimately require anti-TNF therapy. Thus, in such patients it may be preferable to begin with anti-TNF therapy.",
"   </p>",
"   <p>",
"    In adults with RA, early treatment with glucocorticoids might have long-term benefits. In a randomized clinical trial, low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    in addition to the initial DMARD therapy in patients with early active rheumatoid arthritis reduced joint destruction and increased the remission rate over two years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/70\">",
"     70",
"    </a>",
"    ]. A similar study using early low-dose glucocorticoids with DMARD therapy in children with polyarticular JIA is ongoing. The relative benefits versus risks are currently unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Intraarticular glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarticular injections of glucocorticoids appear to be both safe and effective for children with polyarticular JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/33,71\">",
"     33,71",
"    </a>",
"    ]. This was illustrated in a prospective study of hip injections that included a subgroup of 24 patients with polyarticular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/72\">",
"     72",
"    </a>",
"    ]. In this subgroup, 26 of 35 hip joints remitted clinically and by magnetic resonance imaging following one or more injections (performed under general anesthesia in young children or local anesthesia in older children, and with ultrasound guidance when necessary). The incidence of osteonecrosis did not appear to be increased following intraarticular injection when compared retrospectively to the incidence of osteonecrosis prior to the first injection.",
"   </p>",
"   <p>",
"    Similarly, for children with temporomandibular joint involvement, intraarticular glucocorticoid injections have been reported to provide symptomatic relief of pain with minimal side effects in a majority of affected patients. The procedure can be done with computed tomography (CT) or ultrasound-guided imaging, or without imaging by an experienced clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"./temporomandibular-disorders-in-adults?source=see_link\">",
"     \"Temporomandibular disorders in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Injection of intraarticular glucocorticoids into a single inflamed joint is often dramatically effective. However, the need to repeatedly inject the same joint, or to inject multiple joints simultaneously, suggests that more effective systemic therapy is required. With the availability of anti-TNF agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ), the simultaneous injection of multiple joints is indicated infrequently. Children who have active disease in many joints are, in the author's opinion, more likely to experience a desirable long term outcome with advancement to a more effective therapy than with repeated joint injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9391219\">",
"    <span class=\"h3\">",
"     Cyclosporine and azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with continuing active disease despite appropriate treatment with NSAIDs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    have been utilized with varying success in the past [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/33\">",
"     33",
"    </a>",
"    ]. Cyclosporine has been surprisingly effective in children with dactylitis who have not responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    . However, these drugs carry significant potential toxicity and appear to be less effective than the newer biologic agents. As a result most clinicians favor the use of the biologic agents over these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Gold compounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injectable gold was a mainstay of the treatment of adult and juvenile arthritis for decades, largely because more effective disease modifying agents were not available. With the vastly improved therapeutic armamentarium, there is little place for the use of gold compounds in the treatment of arthritis in children today. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25319?source=see_link\">",
"     \"Use of gold compounds in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy is often required for specific complications of JIA, which include management of chronic synovitis, osteoporosis and growth retardation, and uveitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Arthritis",
"    </span>",
"   </p>",
"   <p>",
"    Flexion contractures, weakness, and difficulty with ambulation were frequent complications of polyarticular JIA prior to the introduction of biologic agents. Children presenting with these issues should be referred for physical therapy. Rarely, despite optimal therapy, arthritis progresses to the point at which a joint is severely damaged and becomes nonfunctional. This state is usually, but not always, accompanied by significant pain. Joint replacement is an option that should be seriously considered in children of any age who are nonambulatory or severely limited in ambulation as a result of arthritis. Nonetheless, preservation of the native joint is preferable, particularly in young patients, because the functional life expectancy of an artificial articulation is only 10 to 15 years.",
"   </p>",
"   <p>",
"    Temporomandibular joint involvement is treated in the same way as other joint disease. However, if significant micrognathia develops, surgical correction may be required. This intervention is not undertaken until the facial bones are fully developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Uveitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uveitis is significantly less common than in pauciarthritis, but it nonetheless may occur in up to 5 percent of children with polyarticular JIA. Initially it is treated with topical corticosteroids. If the inflammatory process does not abate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/75,76\">",
"     75,76",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/77,78\">",
"     77,78",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic glucocorticoids may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/79\">",
"     79",
"    </a>",
"    ]. In especially severe disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/80\">",
"     80",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/81\">",
"     81",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/82,83\">",
"     82,83",
"    </a>",
"    ] have been used successfully.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil may be beneficial in children who have not responded to these therapies.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    , however, does not seem to benefit ocular inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Osteoporosis and growth retardation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis and growth retardation associated with severe polyarticular JIA may lead to lifelong disability. Preliminary studies of growth hormone therapy have shown some improvement in bone mineral content [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/85,86\">",
"     85,86",
"    </a>",
"    ] and accelerated linear growth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. However, the use of growth hormone therapy also has been associated with an increased incidence of deformities, such as scoliosis. These abnormalities are postulated to be due to an uneven response to growth hormone, with accelerated and limited growth occurring in undamaged and damaged areas, respectively.",
"   </p>",
"   <p>",
"    Preliminary results suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    may be useful for the treatment of children with JIA and established osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/89\">",
"     89",
"    </a>",
"    ]. The evidence is not of high quality, however, and the safety of using these agents in children remains unproven. In view of the tendency of bisphosphonates to slowly leach from bones for years or decades after even short-term use, better studies are needed to clarify their role in children with JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/48/17162/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With increasing experience utilizing combinations of drugs and the development of a number of biologic agents, it is apparent that our approach to children with polyarticular juvenile idiopathic arthritis (JIA) is rapidly evolving. Prompt initiation of therapy that provides relief of arthritic symptoms and preservation of function is critical to an improved outcome.",
"   </p>",
"   <p>",
"    Our current recommendation is directed toward treating the underlying synovitis and associated inflammation as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial therapy with nonsteroidal inflammatory drug (NSAID) for symptomatic relief. If there is no response to the initial NSAID by three weeks, the first NSAID if discontinued, and a second NSAID may be substituted. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initiation of a second-line drug is recommended unless there is very mild disease. We recommend the use of either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      at a dose of 10",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      <span class=\"nowrap\">",
"       BSA/week,",
"      </span>",
"      or immediate use of a biologic agent that inhibits tissue necrosis factor (TNF), either alone or in combination with methotrexate, remembering that methotrexate is ineffective in predominantly axial arthritis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Methotrexate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'TNF inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With failure to respond to the above regimen, individualized therapeutic decisions are necessary. Consideration of different options, including the use of combination DMARDs or additional biologic agents, is recommended under the supervision of providers with expertise in pediatric rheumatology. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Disease modifying antirheumatic drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment of complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy for specific complications including debilitating arthritis, uveitis, osteoporosis, and growth retardation may also be required. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment of complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/1\">",
"      Criteria for the classification of juvenile rheumatoid arthritis. Bull Rheum Dis 1972; 23:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/2\">",
"      Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/3\">",
"      Ruperto N, Nikishina I, Pachanov ED, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum 2005; 52:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/4\">",
"      Foeldvari I, Szer IS, Zemel LS, et al. A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol 2009; 36:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/5\">",
"      Celebrex gets committee nod for juvenile arthritis, but safety registry urged. \"The Pink Sheet\" 2006; 68(49):7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/6\">",
"      Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998; 41:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/7\">",
"      Ravelli A, Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol 2000; 27:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/8\">",
"      Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/9\">",
"      Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005; 352:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/10\">",
"      Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/11\">",
"      Vilca I, Munitis PG, Pistorio A, et al. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Ann Rheum Dis 2010; 69:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/12\">",
"      Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012; 64:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/13\">",
"      Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006; :CD004524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/14\">",
"      Muzaffer MA, Schneider R, Cameron BJ, et al. Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1996; 128:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/15\">",
"      Padeh S, Sharon N, Schiby G, et al. Hodgkin's lymphoma in systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol 1997; 24:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/16\">",
"      Kahn P. Juvenile idiopathic arthritis--current and future therapies. Bull NYU Hosp Jt Dis 2009; 67:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/17\">",
"      Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/18\">",
"      Becker ML, Ros&eacute; CD, Cron RQ, et al. Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. J Rheumatol 2010; 37:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/19\">",
"      Tukov&aacute; J, Chl&aacute;dek J, Hroch M, et al. 677TT genotype is associated with elevated risk of methotrexate (MTX) toxicity in juvenile idiopathic arthritis: treatment outcome, erythrocyte concentrations of MTX and folates, and MTHFR polymorphisms. J Rheumatol 2010; 37:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/20\">",
"      Becker ML, Gaedigk R, van Haandel L, et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum 2011; 63:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/21\">",
"      Morgan SL, Baggott JE. Folate supplementation during methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2010; 28:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/22\">",
"      Ebbing M, B&oslash;naa KH, Nyg&aring;rd O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009; 302:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/23\">",
"      Ericson U, Sonestedt E, Gullberg B, et al. High folate intake is associated with lower breast cancer incidence in postmenopausal women in the Malm&ouml; Diet and Cancer cohort. Am J Clin Nutr 2007; 86:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/24\">",
"      Ulrich CM. Folate and cancer prevention: a closer look at a complex picture. Am J Clin Nutr 2007; 86:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/25\">",
"      Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010; 303:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/26\">",
"      Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009; 11:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/27\">",
"      Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010; 62:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/28\">",
"      Lehman TJ. Should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor alpha blockers change the way we treat children with juvenile idiopathic arthritis? Arthritis Rheum 2010; 62:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/29\">",
"      Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64:1263.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration MedWatch. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm (Accessed on September 29, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/31\">",
"      Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010; 69:380.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/bbs/topics/NEWS/2008/NEW01879.html (Accessed on November 23, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/33\">",
"      Wallace CA. On beyond methotrexate treatment of severe juvenile rheumatoid arthritis. Clin Exp Rheumatol 1999; 17:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/34\">",
"      Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/35\">",
"      Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009; 68:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/36\">",
"      Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009; 68:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/37\">",
"      Bracaglia C, Buonuomo PS, Tozzi AE, et al. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J Rheumatol 2012; 39:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/38\">",
"      Otten MH, Prince FH, Twilt M, et al. Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2010; 37:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/39\">",
"      Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/40\">",
"      Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006; 54:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/41\">",
"      Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/42\">",
"      Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/43\">",
"      Simonini G, Giani T, Stagi S, et al. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford) 2005; 44:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/44\">",
"      Tynj&auml;l&auml; P, Lahdenne P, V&auml;h&auml;salo P, et al. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 2006; 65:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/45\">",
"      Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2010; 62:3259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/46\">",
"      Billiau AD, Loop M, Le PQ, et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford) 2010; 49:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/47\">",
"      Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009; 60:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/48\">",
"      Vojvodich PF, Hansen JB, Andersson U, et al. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J Rheumatol 2007; 34:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/49\">",
"      van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011; 38:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/50\">",
"      Dallocchio A, Canioni D, Ruemmele F, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford) 2010; 49:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/51\">",
"      Gartlehner G, Hansen RA, Jonas BL, et al. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol 2008; 27:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/52\">",
"      Prince FH, de Bekker-Grob EW, Twilt M, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register. Rheumatology (Oxford) 2011; 50:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/53\">",
"      Ungar WJ, Costa V, Hancock-Howard R, et al. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken) 2011; 63:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/54\">",
"      Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/55\">",
"      Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56:3096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/56\">",
"      Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010; 69:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/57\">",
"      Lahdenne P, V&auml;h&auml;salo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003; 62:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/58\">",
"      Tynj&auml;l&auml; P, V&auml;h&auml;salo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis 2011; 70:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/59\">",
"      Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/60\">",
"      Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2010; 62:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/61\">",
"      Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/62\">",
"      Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 2004; 4:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/63\">",
"      Giannini EH, Lovell DJ, Silverman ED, et al. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 1996; 23:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/64\">",
"      Brooks CD. Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol 2001; 28:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/65\">",
"      van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998; 41:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/66\">",
"      van Rossum MA, Fiselier TJ, Franssen MJ, et al. Effects of sulfasalazine treatment on serum immunoglobulin levels in children with juvenile chronic arthritis. Scand J Rheumatol 2001; 30:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/67\">",
"      van Rossum MA, van Soesbergen RM, Boers M, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007; 66:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/68\">",
"      Silverman E, Spiegel L, Hawkins D, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2005; 52:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/69\">",
"      Foeldvari I, Wierk A. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol 2010; 37:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/70\">",
"      Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005; 52:3360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/71\">",
"      Young CM, Shiels WE 2nd, Coley BD, et al. Ultrasound-guided corticosteroid injection therapy for juvenile idiopathic arthritis: 12-year care experience. Pediatr Radiol 2012; 42:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/72\">",
"      Neidel J, Boehnke M, K&uuml;ster RM. The efficacy and safety of intraarticular corticosteroid therapy for coxitis in juvenile rheumatoid arthritis. Arthritis Rheum 2002; 46:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/73\">",
"      Arabshahi B, Dewitt EM, Cahill AM, et al. Utility of corticosteroid injection for temporomandibular arthritis in children with juvenile idiopathic arthritis. Arthritis Rheum 2005; 52:3563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/74\">",
"      Ringold S, Torgerson TR, Egbert MA, Wallace CA. Intraarticular corticosteroid injections of the temporomandibular joint in juvenile idiopathic arthritis. J Rheumatol 2008; 35:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/75\">",
"      Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006; 149:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/76\">",
"      Tynj&auml;l&auml; P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008; 47:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/77\">",
"      Tynj&auml;l&auml; P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/78\">",
"      Simonini G, Zannin ME, Caputo R, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford) 2008; 47:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/79\">",
"      Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/80\">",
"      Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 1998; 82:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/81\">",
"      Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 2011; 50:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/82\">",
"      Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 2010; 62:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/83\">",
"      Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res (Hoboken) 2011; 63:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/84\">",
"      Foeldvari I, Nielsen S, K&uuml;mmerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007; 34:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/85\">",
"      Rooney M, Davies UM, Reeve J, et al. Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis. J Rheumatol 2000; 27:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/86\">",
"      Bechtold S, Ripperger P, Bonfig W, et al. Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years. J Rheumatol 2004; 31:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/87\">",
"      Simon D, Lucidarme N, Prieur AM, et al. Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. J Rheumatol 2003; 30:2492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/88\">",
"      Saha MT, Haapasaari J, Hannula S, et al. Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Double blind placebo-controlled followup study. J Rheumatol 2004; 31:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/89\">",
"      Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000; 43:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/48/17162/abstract/90\">",
"      Thornton J, Ashcroft DM, Mughal MZ, et al. Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis. Arch Dis Child 2006; 91:753.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6428 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.102.30.19-ACA6AE24F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17162=[""].join("\n");
var outline_f16_48_17162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THERAPEUTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DISEASE MODIFYING ANTIRHEUMATIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9390825\">",
"      Biologic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - TNF inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Etanercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adalimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Infliximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other biologic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Abatacept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9391095\">",
"      Additional agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9390671\">",
"      - Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9391133\">",
"      - Leflunomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Intraarticular glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9391219\">",
"      - Cyclosporine and azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Gold compounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Osteoporosis and growth retardation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=related_link\">",
"      Classification of juvenile arthritis (JRA/JIA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=related_link\">",
"      Spondyloarthropathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./temporomandibular-disorders-in-adults?source=related_link\">",
"      Temporomandibular disorders in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25319?source=related_link\">",
"      Use of gold compounds in rheumatic diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_48_17163="Abdominal vs vaginal hysterecto";
var content_f16_48_17163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of abdominal and vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Abdominal hysterectomy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vaginal hysterectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Length of stay (days)",
"       </td>",
"       <td>",
"        3.99",
"       </td>",
"       <td>",
"        2.76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Median charge (dollars)",
"       </td>",
"       <td>",
"        5604",
"       </td>",
"       <td>",
"        4166",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhage (percent)",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postoperative fever",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder injury",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any complication",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"       <td>",
"        5.3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in Kovac, SR. Obstet Gynecol 2000; 95:787.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17163=[""].join("\n");
var outline_f16_48_17163=null;
var title_f16_48_17164="Surgery hilar cholangioCA";
var content_f16_48_17164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Outcomes of surgical resection in two cohorts of patients treated for hilar cholangiocarcinoma during a similar time period",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        American cohort",
"       </td>",
"       <td class=\"subtitle1\">",
"        Japanese cohort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of patients undergoing resection",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        122",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Resectability rate",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        25 percent",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        79 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bile duct resection alone",
"       </td>",
"       <td class=\"sublist_other\">",
"        21",
"       </td>",
"       <td class=\"sublist_other\">",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start sublist1\">",
"        Liver plus bile duct resection",
"       </td>",
"       <td class=\"sublist_other_start sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other_start sublist_other\">",
"        109",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2 sublist2\">",
"        With caudate lobe resection",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"       <td class=\"sublist_other\">",
"        109",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2 sublist2\">",
"        With portal vein resection",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2 sublist2\">",
"        With pancreaticoduodenectomy",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-year survival overall",
"       </td>",
"       <td>",
"        7 percent",
"       </td>",
"       <td>",
"        16 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-year survival overall",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td>",
"        12 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-year survival in completely resected patients",
"       </td>",
"       <td>",
"        43 percent",
"       </td>",
"       <td>",
"        25 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-year survival in completely resected patients",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td>",
"        18 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Tsao JI, et al. Ann Surg 2000; 232:166.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17164=[""].join("\n");
var outline_f16_48_17164=null;
var title_f16_48_17165="Tdap Td contraindications";
var content_f16_48_17165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications and precautions to diphtheria, tetanus, and pertussis vaccines for children and adolescents aged 7 through 18 years",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Precautions*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neither contraindications nor precautions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Tdap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Severe allergic reaction (eg, anaphylaxis) after a previous vaccine dose or to a vaccine component",
"       </td>",
"       <td>",
"        Moderate or severe acute illness with or without fever",
"       </td>",
"       <td>",
"        History of extensive limb-swelling reaction after a previous dose of DTwP/DTaP or Td immunization that was not an Arthus-type hypersensitivity reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous doses of DTwP/DTaP/Tdap",
"       </td>",
"       <td>",
"        Guillain-Barr&eacute; syndrome within 6 weeks of tetanus toxoid-containing vaccine",
"       </td>",
"       <td>",
"        Stable&nbsp;neurologic disorder (eg, well-controlled seizures, history of seizure disorder, cerebral palsy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Progressive or unstable neurologic disorder, uncontrolled seizures or progressive encephalopathy until a treatment regimen has been established and the condition stabilized",
"       </td>",
"       <td>",
"        Brachial neuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        History of Arthus-type hypersensitivity reaction following diphtheria or tetanus toxoid-containing vaccine (including MCV4)",
"       </td>",
"       <td>",
"        Non-anaphylactic latex allergy",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Breastfeeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Immunosuppression, including HIV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Use of antimicrobials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Tetanus toxoid, reduced diphtheria toxoid (Td, adult Td, dT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Severe allergic reaction (eg, anaphylaxis) after a previous vaccine dose or to a vaccine component",
"       </td>",
"       <td>",
"        Moderate or severe acute illness with or without fever",
"       </td>",
"       <td>",
"        (As for Tdap)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Guillain-Barr&eacute; syndrome within 6 weeks of tetanus toxoid-containing vaccine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        History of Arthus-type hypersensitivity reaction following diphtheria or tetanus toxoid-containing vaccine (including MCV4)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Tdap: tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine; DTaP: diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine; DTwP: diphtheria tetanus, whole-cell pertussis vaccine; Td: tetanus toxoid, reduced diphtheria toxoid (adult Td, dT); MCV4: quadrivalent meningococcal vaccine; HIV: human immunodeficiency virus.",
"     <br>",
"      * Precautions should be reviewed carefully. Benefits and risks of administering specific vaccines to a person under these circumstances should be considered. If the risk from the vaccine is believed to outweigh the benefit, the vaccine should not be administered.",
"      <br>",
"       &bull;",
"       <font color=\"black\">",
"        Vaccines that contain latex (eg, in the tip or rubber plunger) are contraindicated in patients with anaphylactic reactions to latex. Check the prescribing information for information about latex.",
"       </font>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Immunization Action Coalition. Guide to contraindications and precautions to commonly used vaccines. Available at:",
"        <a href=\"file://www.immunize.org/catg.d/p3072.pdf\">",
"         www.immunize.org/catg.d/p3072.pdf",
"        </a>",
"        . Accessed on June 23, 2012.",
"       </li>",
"       <li>",
"        Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.&nbsp;",
"       </li>",
"       <li>",
"        American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK. (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.553.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17165=[""].join("\n");
var outline_f16_48_17165=null;
var title_f16_48_17166="Functional constipation barium";
var content_f16_48_17166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Functional constipation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This unprepped barium enema is compatible with functional constipation. The rectum is mildly dilated with stool and there is no evidence of obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George D Ferry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17166=[""].join("\n");
var outline_f16_48_17166=null;
var title_f16_48_17167="Ulcer with clean base Endosc";
var content_f16_48_17167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulcer with a clean base",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The opalescent ulcer in the center of this image taken during endoscopy has a \"clean\" base, which has a low risk of bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_48_17167=[""].join("\n");
var outline_f16_48_17167=null;
